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Così diventò tutto piccolo
anche le notti là in America
Ti volti e vedi la tua vita
come la bianca scia di un’elica
(Caruso, Lucio Dalla, 1986) 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SUMMARY
The overall focus of thesis is determining key disease-driving molecular pathways involved 
in the progression of a specific subtype of neuromuscular diseases, the collagen type VI-related 
muscular dystrophies (COL6RD). These kinds of muscular disorder encompass a wide spectrum of 
diseases,  ranging  from  the  severe  Ullrich  muscular  dystrophy  (UCMD)  to  the  mild  Bethlem 
myopathy  (BM),  characterized  by  a  plethora  of  clinical  manifestations.  Both  UCMD and  BM 
usually arise at birth or early childhood with hypotonia and progressive muscle weakness, joint 
contractures and hyperlaxity of the distal joints. In UCMD, ambulation is achieved with a delay of 2 
years  compared  to  healthy  children,  but  it  is  eventually  lost.  In  BM,  ambulation  is  generally 
maintained and only few affected individuals require wheel chair. Genetically, UCMD and BM are 
caused by mutations in the genes encoding for the three α-chains of the collagen type VI acting in a 
recessive or dominant way. Morphologically, the muscle biopsies of UCMD and BM patients are 
characterized  by  variable  degree  of  atrophy,  fibrosis,  and  regeneration  and degeneration  of  the 
muscle fibers. 
In  the  present  work,  we systematically  reviewed and classified a  cohort  of  22 COL6RD 
patient muscle biopsies and 14 age-matched control muscle biopsies according to basic histological 
features, such as muscle fibers atrophy and fibrosis. This classification was achieved through an 
innovative  automatic  image  analysis  algorithm  and  generated  three  groups,  COL6RD-1, 
COL6RD-2 and COL6RD-3, of increasing histological severity. Microarray-based gene expression 
profiling and RNA-Seq of the same cohort produced gene expression fingerprint that suggested a 
strong segregation  of  COL6RD muscle  biopsies  from the  control  muscle  biopsies,  but  did  not 
clearly correlated with the histological grouping established among the patients. In silico analysis of 
the  gene  expression  results  revealed  TGFβ1  pathway  as  the  major  regulator  of  the  COL6RD 
histological  changes  and,  most  likely,  of  the  underlying  disease  pathophysiology.  TGFβ1 
involvement was further confirmed by upstream regulator analysis, validation of downstream gene 
targets by qRT-PCR, and protein targets by western blot and immunofluorescence. Moreover, we 
also found a downregulation of skeletal muscle specific genes.
RNA-Seq data also highlighted a deeper level of regulation of the gene expression carried 
over by alternative splicing. We identified 43 genes having more than one splice isoform whose 
expression level was significantly different between COL6RD muscle biopsies and controls, with 
DECORIN being the one displaying the highest number of alternatively spliced isoforms.
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Overall, this study suggests that different histological stages of COL6-RD are characterized 
by the same pattern of gene expression, involving predominantly the upregulation of matricellular 
components, even when the muscle involvement is not evident yet, and downregulation of muscle 
specific genes.  Our  results  also  suggest  that  TGFβ1 acts  as  a  major  driver  of  the  pathological 
changes  at  the  skeletal  muscle  level.  Moreover,  muscle  biopsies  from  COL6-RD  patients  are 
characterized by an increase in alternative spliced isoforms of extracellular matrix-related genes that 
might contribute to the pathogenesis of the disease. 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SOMMARIO
L’obiettivo di questa tesi è determinare i meccanismi molecolari coinvolti nella progressione 
di un sottogruppo specifico di malattie neuromuscolari: le distrofie muscolari congenite causate da 
deficit di collagene di tipo VI. Questo gruppo di distrofie comprende un ampio spettro di disordini 
caratterizzati da un ampio spettro di manifestazioni cliniche: dalla più grave distrofia muscolare 
congenita di Ulrich (UCMD) alla più moderata miopatia di Bethlem” (BM). Sia UCMD che BM si 
manifestano  alla  nascita  o  nel  prima infanzia  con  ipotonia  e  debolezza  muscolare  progressiva, 
contrazioni delle articolazioni prossimale e iperelasticità delle articolazioni distali. Individui affetti 
da UCMD iniziano a deambulare con un ritardo di 2 anni rispetto ad individui sani, e la capacità 
deambulatoria viene poi persa nuovamente. Individui affetti da BM, invece, conservano la capacità 
di ambulare e solo pochi necessitano di sussidi. Dal punto di vista genetico, UCMD e BM sono 
causate da mutazioni che possono colpire uno o più geni codificanti le tre molecole del collagene di 
tipo VI. Tali mutazioni possono agire in modo dominante o recessivo. Morfologicamente le biopsie 
muscolari  di  pazienti  affetti  da  UCMD e  BM sono caratterizzate  da  atrofia  muscolare,  fibrosi, 
rigenerazione e degenerazione delle fibre muscolare, evidenziata dalla presenza di aree necrotiche.
Nel  presente  lavoro,  abbiamo  effettuato  un’analisi  sistematica  di  22  biopsie  muscolari 
ottenute da pazienti  affetti  da COL6RD e 14 biopsie muscolari  ottenuti  da controlli  sani di  età 
corrispondente,  che sono state suddivise in base al  grado di  atrofia muscolare e fibrosi.  Questa 
classificazione  è  stata  effettuata  usando  un  algoritmo  originale  per  l’analisi  automatica  di 
preparazioni  istologiche,  ed ha generato 3  gruppi,  COL6RD-1,  COL6RD-2 and COL6RD-3,  di 
gravità istologica crescente. Le stesse biopsie sono state sottoposte a microarray e RNA-Seq ed 
hanno rivelato andamenti di espressione genica in forte correlazione con i gruppi definiti secondo 
secondo i preparati istologici, sottolineando la chiara divisione tra le biopsie muscolari di individui 
affetti  da  COL6RD  e  controlli.  L’analisi  in  silico  dell’espressione  genica  ha  successivamente 
rivelato  TGFβ1   come  il  maggior  responsabile  dei  cambiamenti  istologici  in  COL6RD  e, 
verosimilmente,  dei  processi  patofisiologici  sottostanti.  Il  coinvolgimento  di  TGFB1  è  stato 
ulteriormente confermato dall’ upstream regulator analysis, validazione di geni target downstream 
tramite qRT-PCR, e di proteine effettrici tramite western blot e immunofluorescenza. I dati ottenuti 
tramite RNA-Seq hanno rivelato un ulteriore livello di regolazione dell’espressione genica attuato 
tramite  splicing  alternativo.  Abbiamo  identificato  43  geni  aventi  più  di  una  variante  la  cui 
espressione è significativamente diversa tra biopsie muscolari di COL6RD e controlli sani. Nello 
specifico, Decorin è il gene con il maggior numero di isoforme originate da splicing alternativo.
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Nel  complesso,  questo  studio  suggerisce  che  i  diversi  stadi  istologici  di  COL6RD sono 
caratterizzati dallo stesso profilo di espressione genica, che coinvolge prevalentemente l’aumento di 
componenti della matrice extracellulare, anche in mancanza di evidenze istologiche di fibrosi, e la 
diminuzione di prodotti di geni muscolo-specifici.
I nostri risultati suggeriscono anche che ci siano pathway molecolari TGFβ1-dipendenti che 
agiscono  da  principali  regolatori  dei  cambiamenti  patologici  a  livello  del  muscolo  scheletrico. 
Inoltre, le biopsie muscolari provenienti da pazienti affetti da COL6RD sono caratterizzate da un 
aumento delle isocrone geniche generate da splicing alternativo, soprattutto per geni coinvolti nella 
produzione e nel mantenimento della matrice extracellulare.   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1 - INTRODUCTION
COLLAGEN TYPE VI-RELATED MUSCULAR DYSTROPHIES
1.1 - CLINICAL FEATURES
Collagen type  VI-related  muscular  dystrophies  (COL6RD) are  a  clinically  heterogeneous 
group of neuromuscular disorders characterized by muscle weakness and hypotonia, proximal joint 
contractures and distal joint hyperlaxity noted at birth or early infancy. COL6RD can be ideally 
represented by a spectrum of conditions, with Ullrich congenital muscular dystrophy being at the 
most severe end, and Bethlem myopathy being the milder end.
Ullrich Congenital Muscular Dystrophy (UCMD) was originally described by Otto Ullrich 
in 1930 as a congenital muscular dystrophy that he called “scleroatonic muscular dystrophy”. In the 
late ‘70s the same condition was reported in four Japanese individuals. Two of them were siblings 
from consanguineous parents with clinical history of muscular disorders. The other two patients 
were unrelated. All of them were described as floppy at birth. They were never able to crawl or 
walk, or they acquired ability to walk later in infancy but they lost it very soon. Muscle weakness 
was slowly progressive, with the distal muscles being preferentially involved. Serum creatine kinase 
(CK) levels  were normal.  Electromyographic examination showed a myopathic  pattern.  Muscle 
biopsies from the four patients showed dystrophic features: variation in muscle fiber size, adipose 
tissue replacement, centrally located nuclei. All four patients were very intelligent (Furukawa & 
Toyokura, 1977). 
UCMD was also reported in two Italian siblings from healthy, non consanguineous parents, 
with relatively late onset. Both patients were healthy at birth, but they started to develop progressive 
muscle weakness, wobbly gait, difficulty climbing stairs, and distal joint hyperlaxity around 3 years 
of age. At the age of 7 years they started to develop major proximal joints contractures and rigid 
spine. They both showed progressive decreased respiratory capacity. Muscle biopsy of the deltoid 
muscle showed variation in fiber size, reduction of the muscular component that was replaced by 
connective tissue, prominent mostly in the endomysium and perimysium, and fat tissue. CK levels 
were normal or mildly elevated. Intellectual development was normal for both siblings (Ricci et al., 
1988). 
Bethlem Myopathy (BM) was originally described in the late ’70 in 3 Dutch families in 
which 28 patients were affected by a benign myopathy with autosomal dominant inheritance. The 
onset  of  the disease was noted early in infancy,  approximately at  the age of five,  although the 
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patients were not born as floppy babies.  Developmental  milestones were achieved normally.  At 
young age, many patients tended to fall down easily, they could not run as fast as their peers, and 
they  had  difficulty  at  gymnastics  with  jumping  and  skipping.  After  this  early  manifestation  of 
symptoms, the progression of the disease was otherwise very slow. The benign character of the 
disorder is testified by the fact that life expectancy was not shortened. The patients presented with a 
generalized  muscle  weakness  and  muscle  atrophy  in  adulthood.  Proximal  muscles  were  more 
affected than distal, and the extensor muscles more than the flexors. Contractures of the elbows, 
ankles and of the interphalangeal joints of the last four fingers were also present. Muscle biopsies 
revealed marked variation in fiber size and marked increased in fatty tissue. CK levels were normal 
or only mildly elevated (Bethlem & Wijngaarden, 1976). Many case reports followed afterwards 
describing the  same benign autosomal  dominant  neuromuscular  disorder  characterized by early 
onset but very slow progression, elbows and ankles contractures and mild non-specific myopathic 
changes  on  histology (Arts,  Bethlem,  & Volkers,  1978;  Leyten  et  al.,  1986;  Merlini,  Morandi, 
Granata, & Ballestrazzi, 1994; Mohire et al., 1988). 
Studies based on muscle magnetic resonance imaging (MRI) revealed a very specific pattern 
of  muscle  involvement  concerning  both  Bethlem  myopathy  and  Ullrich  congenital  muscular 
dystrophy patients (Mercuri et al., 2002; Mercuri et al., 2003; Mercuri et al., 2005). Severe clinical 
phenotype are usually associated with severe and diffuse involvement of the calf muscle and of the 
thigh  muscles,  with  relative  sparing  of  sartorius,  gracilis,  adductor  longus  and  rectus.  Vastus 
lateralis is peculiar in that it shows the typical pattern of concentric involvement, while the rectus 
femoris is characterized by fatty tissue infiltration under the central fascia, also known as central 
shadow.  Moderate  clinical  manifestations  reflect  a  moderate  muscle  involvement,  with  only 
minimal changes in the mildest cases.  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Figure  1:  Joint  laxity  and  progressive 
joint  contractures  in  patients  with 
UCMD and BM. (a,b) Typical distal joint 
hyperlaxity,  particularly  in  the  finger,  in 
patient  with  UCMD.  (c)  Contractures  of 
the  major  joint  (shoulders,  elbows,  and 
knees)  in  a  patient  with  UCMD.  (d,e) 
Contractures  of  the  Achilles  tendon  and 
finger  flexor  in  a  patient  with  BM.  (f) 
Contractures of shoulder and elbow joints 
in a patient with BM (Bonnemann, 2011) 
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respiratory support has led to the death of teenagers with 
Ullrich CMD.
Careful studies are now required to establish the long-
term course of the disease under the current standards 
of medical care. Early data on the long-term outcomes of 
patients with Ullrich CMD are difficult to evaluate, as 
much of that experience was gathered from patients who 
had not received active respiratory intervention, with the 
result that many of these individuals succumbed to respi-
ratory failure in their late teenage years.7 With the avail-
ability of effective respiratory interventions, other aspects 
of the disease could potentially surface now that patients 
with Ullrich CMD routinely survive into adulthood.
Intermediate collagen VI-related myopathies
Presentation
Patients with collagen VI-related myopathies of inter-
mediate severity cannot be easily classified as having 
either Ullrich CMD or Bethlem myopathy. No exact defi-
nitions exist yet as to where the Ullrich CMD phenotype 
stops and the intermediate-severity phenotype begins. 
Similarly, at the other end of the range, a transition from 
intermediate-severity disease to the classic Bethlem 
pheno type occurs. To define this disease spectrum, and 
to determine whether discrimination between the various 
phenotypes is possible, an international study captur-
ing the range of phenotypic expression in patients with 
collagen VI-related myopathies is currently underway.
Patients with intermediate phenotypes of colla-
gen VI-related myopathies were referred to as having 
‘mild’ early-onset collagen VI myopathy in the French 
series.12 Similarly to children with Ullrich CMD, these 
patients also typically present in the neonatal period but 
achieve the ability to walk, usually ambulating into young 
adulthood and sometimes beyond. They are, therefore, 
considered to have a milder form of disease than patients 
with the typical Ullrich CMD phenotype. However, most 
of the clinical features outlined for Ullrich CMD will still 
be clearly recognizable in these patients.
Course of disease
Although contractures are not necessarily prominent early 
on in intermediate-severity disease, they start to develop 
during childhood and are progressive, particularly in the 
ankles and the elbows, but also in the knees. Scoliosis 
and/or spinal rigidity can be marke . Patients might be 
able to walk for limited distances, particularly on flat sur-
faces and indoors, but they may require assistance such 
as a mobility scooter for prolonged ambulation. However, 
spending increased amounts of time in the sitting posi-
tion will aggravate contractures of the knee flexors and 
the hips, and further interfere with the patient’s ability to 
walk. Upright mobility should, therefore, be maximized 
for as long as possible.
Progressive respiratory insufficiency is also of concern 
in patients with intermediate phenotypes of colla-
gen VI-related myopathy, and a consistent decline in the 
percentage of predicted forced vital capacity is observed 
in the early teenage years.11 This group of patients is again 
particularly susceptible to nocturnal respiratory insuffi-
ciency, which can develop even in individuals who are 
still able to walk and, therefore, careful monitoring of 
these patients is required.11
Bethlem myopathy
Presentation
Considerable variability exists within the Bethlem myo-
pathy phenotype. Many of the same clinical problems 
Figure 1 | Joint laxity and progressive joint contractures in patients with Ullrich CMD and Bethlem myopathy. a,b | Typical 
pronounced distal hyperlaxity seen in children with Ullrich CMD, particularly in the fingers. c | A patient with typical Ullrich 
CMD who had an initial period of ambulation but can no longer walk—note evolving contractures in the shoulders, elbows 
and knees, round face with mild facial erythema, as well as distal joint laxity. d | Pronounced Achilles tendon contractures 
in a teenager with Bethlem myopathy. e | Typical long finger flexor contractures in an adult patient with Bethlem myopathy 
prevent full extension of the fingers when the palms are placed together with dorsiflexed hands and elevated elbows (the 
‘Bethlem sign’). f | An adult with Bethlem myopathy. The typical upper body posture results from contractures at the elbows 
and shoulders. She also has contractures of the Achilles tendons. Abbreviation: CMD, congenital muscular dystrophy. 
Written consent for publication was obtained from the father of the patient featured in part c.
a c d
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b
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1.2 - ETIOLOGY
COL6A1 and COL6A2 are both located on chromosome 21q22.3. They code for the α1(VI) 
and  the  α2(VI).  COL6A3  is  located  on  2q37  and  codes  for  the  α3(VI)  chain.  COL6A1  and 
COL6A2 are located in a head-to-tail fashion, separated by an intermediate region of approximately 
93kb. COL6A3 is regulated independently from COL6A1 and COL6A2(Chu et al., 1989; Lamande, 
Sigalas, et al., 1998).
Collagen type VI-related muscular dystrophies (COL6RD) are caused by mutations in any of 
three genes encoding the subunits of collagen type VI. Both Ullrich congenital muscular dystrophy 
and Bethlem myopathy are inherited as autosomal dominant or recessive conditions. However, de 
novo dominant-acting mutations account for the majority of UCMD cases, and autosomal recessive 
BM are a very rare event (Baker et al., 2005; Foley et al., 2009; Gualandi et al., 2009). A variety of 
mutations at the genomic or coding DNA level are known to cause COL6RD. 
The most common events that lead to UCMD and BM are heterozygous missense mutations 
on COL6A1, COL6A2 or COL6A3 genes that cause amminoacid substitutions affecting different 
domains of the α1(VI), α2(VI), and α3(VI) subunits of the collagen VI protein. The most common 
effects are changes in the Gly residue of the invariable Gly-X-Y motif at the triple helical domain or 
at the N-terminal or C-terminal globular domains of the α1(VI), α2(VI), and α3(VI) (Demir et al., 
2002; Jobsis et al., 1996; Pan et al., 1998; Pepe, Bertini, et al., 1999; Scacheri et al., 2002; Vanegas 
et al., 2002). Mutations causing premature termination and in-frame deletions can also affect the 
mRNA maturation, leading to skipping of exons or truncation of the mRNA harboring the mutation, 
preventing the biosynthesis of fully functional α-chains (Lamande, Bateman, et al., 1998; Lampe et 
al., 2008; Pepe, Giusti, et al., 1999; Pepe et al., 2006; Vanegas et al., 2002). Nonsense-mediated 
decay of the mRNA carrying the mutations is also a mechanism commonly found in UCMD and 
BM patients(Lampe et al., 2008; Lucarini et al., 2005; R. Z. Zhang et al., 2002). 
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Figure  2:  Muscle  MRI  of  patients 
with UCMD and BM. (a-d) BM (e-h) 
UCMD. T1-weighted MRI scans show 
areas of fatty tissue replacement in the 
typical  “outside-in”  pattern.  The 
involved  areas  are  the  center  of  the 
rectum femoris (long arrows) and the 
vastus  lateralis  (arrowheads) 
(Bonnemann, 2011)
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Attachment of cells to the extracellular matrix is 
important for preventing apoptosis in general,75 which 
could be particularly relevant for muscle disorders that 
directly involve interactions between matrix and muscle, 
as is the case for both collagen VI-related and LAMA2-
related CMDs.76–78 Work in cell cultures has shown that 
collagen VI-deficient cells exhibit decreased adherence 
to their surroundings,60,79 emphasizing the importance of 
this muscle cell–extracellular matrix interface.
Genotype–phenotype correlations
So far, all collagen VI mutations associated with the 
Ullrich CMD, intermediate or Bethlem myopathy spectra 
of disorders have occurred in the COL6A1, COL6A2 and 
COL6A3 genes,10 while no mutations have been observed 
to date in the newly rec gnized human collagen VI 
chains (COL6A5 and COL6A6).43,44
A genetic spectrum clearly underlies the clinical vari-
ability that is seen in the collagen VI-related myopathies. 
Although researchers initially thought that recessive 
mutations in the collagen VI genes underlie Ullrich 
CMD and that dominant mutations underlie Bethlem 
myopathy, this distinction is no longer valid. Ullrich 
C D occurs through both recessive and dominant 
genetic mechanisms, the latter most typically as de novo 
autosomal-dominant mutations. In fact, in populations 
with a low degree of consanguinity, de novo autosomal-
dominant mutations are the most common under-
lying mechanism of Ullrich CMD.1,30,32,80 Furthermore, 
although the typical genetic mechanism and pattern of 
inheritance for Bethlem myopathy is dominant, recessive 
mutations have also been seen in affected patients, albeit 
rarely.81,82 For example, the myosclerosis phenotype15 has 
emerged as a recessive form of Bethlem myopathy, in 
which a homozygous nonsense mutation in the COL6A2 
gene results in a stable chain lacking the C2 domain but 
retaining the C1 domain,16 which presumably interferes 
with its ability to interact with other components in the 
extracellular matrix. 
Recessive mutations that underlie typical Ullrich CMD 
mostly lead to complete absence of collagen VI in the 
extracellular matrix in muscle and in dermal fibroblast 
cultures.83 Such functional null alleles may be caused by 
nonsense mutations83 as well as splice-site mutations 
and intragenic deletions resulting in an out-of-frame 
transcript29,83,84 or in an assembly-incompetent chain 
(if located towards the C-terminal end of the colla-
genous triple- helical domain).80 If nonsense mutations 
affect alternatively spliced parts of the gene, such as 
the N-terminal globular domain of the c llagen α3(VI) 
chain, their pheno typic effect can be milder than those 
of nonsense mutations in other sites.1,85–87
Although intragenic deletions in collagen VI loci have 
been recognized,88,89 large-scale genomic deletions can 
clearly also occur in the COL6A1 and COL6A2 locus on 
chromosome 21, encompassing the entirety of one or 
both of the collagen VI genes located there, or parts of 
one of the genes. Complete deletions of one copy of these 
genes also act in a recessive fashion, meaning that carriers 
of the deletion are clinically asymptomatic until a second 
mutation is present on the other allele. This charac teristic 
also means that complete haploinsufficiency of all three 
collagen VI genes is not associated with clinical diseas . 
Although homozygous missense mutations are a less 
common cause of severe Ullrich CMD than the null 
mutations discussed above, they have been described. 
Such mutations presumably affect crucial functions of 
the collagen VI protein and its interactions.16,90
a c db
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Figure 3 | Muscle MRI findings in patients with collagen VI-related myopathies. T1-weighted MRI scans of the thigh in 
patients with a–d | Bethlem myopathy and e–h | Ullrich congenital muscular dystrophy of variable severity. Characteristic 
fatty degeneration (white areas) is seen along the fascia in the center of the rectus femoris (long arrows) and along the rim 
of the vastus lateralis (arrowheads)—the characteristic ‘outside-in’ pattern. The findings in parts d and h are still visible in 
the patients with severe forms of these diseases. Permission obtained from Elsevier Ltd © Mercuri, E. Neuromuscul. 
Disord. 15, 303–310 (2005).
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Three additional collagen VI genes were identified and characterized, COL6A4, COL6A5, 
and  COL6A6  (Fitzgerald,  Rich,  Zhou,  &  Hansen,  2008;  Gara  et  al.,  2008).  These  genes  are 
clustered  at  a  single  genomic  locus  on  chromosome  3,  3p24.3,  which  is  very  conserved  in 
mammals. The products of these genes are three α-chains, α4(VI), α5(VI), and α6(VI). In humans, 
COL6A6 is widely expressed, but COL6A5 is more limited. COL6A4, instead, is not expressed in 
humans due to a disruption of the gene occurred during the speciation process. In mouse, Col6a5 
and Col6a6 are expressed in a wide range of tissues. Col6a4 is limited to few tissues, such as uterus 
and ovary. 
Interestingly, in vitro studies have shown that α5(VI) and α6(VI) chains are not competent to 
assemble with the three main α-chains of collagen VI, α1(VI), α2(VI), and α3(VI). However, to 
date, there are no reported mutations in the COL6A5 and COL6A6 genes in patients affected by 
COL6RD, and their involvement in human diseases remains unknown. 
1.3 - PATHOGENESIS
1.3.1 - Collagen type VI Structure
Collagen type VI protein is composed by three polypeptides, α1(VI), α2(VI), and α3(VI) 
chains, that assemble in stoichiometric proportions. 
COL6A1 consists of a total of 36 exons: 7 code for the globular N-terminal domain of α1(VI) 
chain, one fusion exon coding for the final part of the N-terminal domain and the initial part of the 
triple helical domain, 19 coding uniquely for the triple helical domain, and 9 coding for the C-
terminal domain. α1(VI) C-terminal domain can be further subdivided in two subdomains: C1 and 
C2 (Trikka, Davis, Lapenta, Brahe, & Kessling, 1997).
COL6A2 consists of a total of 28 exons: 4 exons code for the N-terminal domain of the 
α2(VI) chain, one fusion exon coding for the final part of the N-terminal domain and the initial part 
of the triple helical domain, 18 coding uniquely for the triple helical domain, and 5 coding for the 
C-terminal  domain.  The  C-terminal  domain  of  α2(VI)  is  encoded  by  two  exons  that  undergo 
alternative splicing and originate two different C-termini (Saitta, Timpl, & Chu, 1992).
COL6A3 consists of a total of 44 exons: 12 exons code for the N-terminal domain of the 
α3(VI) chain, one fusion exon coding for the final part of the N-terminal domain and the initial part 
of the triple helical domain, 18 coding uniquely for the triple helical domain, and 12 coding for the 
C-terminal  domain.  Exons from the N-terminal  and C-terminal  domains undergo tissue-specific 
alternative splicing originating multiple transcripts (Stokes, Saitta, Timpl, & Chu, 1991).
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The triple helical region of each α-chain is characterized by continuous Gly-X-Y repeats, two 
key cysteine residues, and abundance of RGD (Arg-Gly-Asp) tripeptide sequence, important for cell 
binding activity. The triple helical domain of α1(VI) is coded by 18 small exons and contains three 
RGD sequences. The triple helical region of α2(VI) is coded by 19 exons and contains five RGD 
sequences (Saitta et al., 1991).
Assembling of the fully functional collagen type VI protein is carried over intracellularly and 
extracellularly. Inside the cell, the three α-chains assemble to form monomers. Two monomers are 
laterally aligned in an antiparallel fashion, with the globular domain interacting with the adjacent 
helix, to form disulfide-bonded dimers. Two dimers form tetramers that are stabilized by disulfide 
bonds  formed  within  the  triple  helical  domains.  The  tetramers  are  then  exported  into  the 
extracellular  space,  where  they  assemble  in  a  end-to-end  fashion  to  form  beaded-looking 
microfibrils (Bruns, 1984; Kuo, Keene, & Glanville, 1995)(Chu et al., 1987; Engel et al., 1985).
1.3.2 - Collagen type VI Function
Collagen type VI is a non fibrillar collagen expressed in many connective tissues and that is 
implicated in the extracellular matrix organization. In skeletal muscle, collagen type VI is produced 
by the interstitial fibroblasts and it  is thought to anchor the basement membrane in the skeletal 
muscle by interacting with collagen IV, a  major component  of  the basal  lamina (Kuo,  Maslen, 
Keene, & Glanville, 1997; Zou, Zhang, Sabatelli, Chu, & Bonnemann, 2008).
1.3.3 - Pathophysiology
COL6RD affects two major bodily compartments: extracellular matrix and skeletal muscle. 
With regards to the extracellular matrix, the collagen VI protein can be reduced, mislocalized, or 
completely absent.  We have previously described how apparently similar mutations in the three 
collagen  VI  genes,  COL6A1,  COL6A2,  and  COL6A3,  cause  both  mild  Bethlem  myopathy 
phenotype  and  severe  Ullrich  congenital  muscular  dystrophy phenotype.  The  outcome depends 
greatly on the position of the mutation, the extension of the involvement of the collagen VI genes, 
and the consequences that these have on the complex biosynthesis of the collagen VI monomers, 
dimers, tetramers, and ultimately of the microfibrils. 
Generally speaking, mutations that affect the globular C-terminal domain of any of the α-
chains have more severe consequences than mutations affecting the N-terminal domain. Mutations 
affecting  the  triple  helical  domain  of  any  of  the  α-chains  can  have  more  severe  or  milder 
consequences according to their relative position respect to the C-terminal or N-terminal domain, 
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and to the amminoacid sequence that they affect. Moreover, the extend of the downstream effects 
depends also on the ability of the mutated α-chains to be incorporated into monomers,  dimers, 
tetramers and microfibril of collagen VI, and the grade of dominant-negative effect that they exert 
on the assembly of monomers, dimers, and tetramers. 
In frame deletions  
Heterozygous mutations causing in-frame deletions and resulting in exon skipping have 
been reported for both Bethlem myopathy and Ullrich congenital muscular dystrophy. In studies 
previously published studies, the exons skipping involved exon 14 of the α1(VI), exon 11 of the 
α2(VI),  exon 15 of the α3(VI),  all  of them located within the triple helical domain of α1(VI), 
α2(VI) and α3(VI) (Baker et al., 2007; Lamande, Shields, Kornberg, Shield, & Bateman, 1999; Pan 
et al., 2003; Pepe, Giusti, et al., 1999)
The skipping of any exon in the coding DNA of COL6A1, COL6A2, and COL6A3 would 
lead to  the  synthesis  of  internally  deleted α-chains  with  possibly  compromised ability  to  form 
monomers, dimers, and tetramers, depending on the quality of the defects. If the α-chains were 
severely structurally compromised or the deletion affected critical amino acid residues necessary for 
the stability of the collagen VI protein, for example cysteine residues necessary for the formation of 
disulfide  bonds  between  monomers  and  dimers,  the  monomers  would  not  associate  into  more 
complex structures, and the mutated α-chain would not be secreted. Because the mutation appears 
in  homozygosity,  and  stable  collagen  VI  monomers  forms  with  the  stoichiometry  1  α1(VI):  1 
α2(VI): 1 α3(VI), the result is the strongly reduced amount of structurally normal collagen VI in the 
extracellular matrix. 
Mutations  causing  in-frame  deletions  exerting  a  strong  dominant-negative  effect  and 
compromising  the  intracellular  assembly  of  dimers,  tetramers,  and  extracellular  microfibrils, 
generally  result  in  a  severe  deficiency  of  collagen  VI  in  the  extracellular  matrix  that  can  be 
associated with a severe Ullrich congenital muscular dystrophy phenotype. If the mutations was 
located proximal to the N-terminal end of triple helical domain, the patient phenotype would likely 
resemble the mild Bethlem myopathy.  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Glycine substitutions
A class of mutations that  have been associated with both Bethlem myopathy and Ullrich 
congenital muscular dystrophy is Glycine (Gly) substitutions that disrupt the invariable Gly-X-Y 
motif of the triple helical domain (Giusti et al., 2005; Jobsis et al., 1996; Lamande et al., 2002; 
Pepe,  Bertini,  et  al.,  1999;  Sasaki  et  al.,  2000;  Scacheri  et  al.,  2002).  Gly  substitutions  in  the 
conserved Gly-X-Y motif are the most commonly identified mutations in COL6RD, accounting for 
roughly  one  third  of  all  the  pathogenic  mutations  in  COL6A1,  COL6A2,  and  COL6A3.  The 
majority of Gly substitutions in the triple helical domain are de novo, dominantly-acting mutations. 
However, recessive cases have been reported. Interestingly, the dominant negative mutations are 
generally  more  frequently  found  in  the  N-terminal  end  of  the  α-chain  triple  helix,  while  the 
recessive mutations are near the C-terminal end of the triple helical domain. Structural analyses 
have suggested that the critical region important for microfibril formation is the segment included 
between the  Gly-X-Y triplets  10-17,  and mutations  occurring within  the  critical  region are  the 
leading cause of more severe clinical  phenotype.  The seventeenth Gly-X-Y triplet  is  close to a 
cysteine residue on the α3(VI) chain that is essential for tetramers stabilization via disulfide bonds. 
Mutations occurring outside of this critical region, toward the N-terminal end of the triple helix, do 
not prevent the formation of tetramers, although very unstable. The resulting collagen VI deposited 
in the extracellular matrix would contain structural abnormalities that would reduce the efficiency in 
the end-to end association to form microfibrils. Patients presenting these kind of mutations also 
present with a wide spectrum of clinical severity, but generally milder phenotypes likely due to less 
compromised microfibril assembly (Butterfield et al., 2013). 
Nonsense-mediated decay of the mutant mRNA
Nonsense-mediated  decay  has  been  described  both  in  Bethlem  myopathy  and  Ullrich 
congenital muscular dystrophy (Lamande, Bateman, et al., 1998; Lucarini et al., 2005; R. Z. Zhang 
et al., 2002). It is due to insertions and point mutations that are usually the cause of a frameshift that 
ultimately leads to a premature stop codon in the mRNA of any of the collagen VI genes (COL6A1, 
COL6A2, and COL6A3). Premature stop codons in the final exon of a gene do not usually impact 
the mRNA stability, therefore the result is a truncated protein. The result of a premature stop codon 
in any but the final exon of the gene causes, instead, a strong reduction in the stability of the mRNA 
that leads to the absence of the mutant mRNA. The effect of a homozygous mutation that cause s 
nonsense-mediated decay of the mRNA is the complete or extremely severe reduction of the amount 
of collagen type VI produced, with patients carrying these mutations showing a Ullrich congenital 
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muscular dystrophy clinical phenotype. Heterozygous mutations affecting mRNA stability, instead, 
causes protein haploinsufficiency which results in Bethlem myopathy.
Skeletal muscle ultrastructural changes
Defects in collagen type VI are also associated with skeletal muscle ultrastructural changes, 
in Col6a1-/- mice and COL6RD patients (Irwin et al., 2003; Merlini et al., 2008). The structural 
alterations present in Col6a1-/- mice include damaged and irregularly shaped muscle fibers, defects 
in the shape and function of mitochondrial, and altered structure of the sarcoplasmic reticulum (SR). 
Mitochondria  are  known to  respond  to  pathological  conditions  increasing  the  inner  membrane 
permeability via the opening of the permeability transition pore (PTP). Opening of the PTP, in turn, 
alters the handling of the intracellular Ca2+. SR and PTP in Col6a1-/- are involved in the abnormal 
Ca2+ response when handling the excitation-contraction coupling. Moreover, Col6a1-/- muscle fibers 
have more apoptotic nuclei compared to normal control muscles. This was also proved in COL6RD 
patients.  The  mitochondrial  dysfunction  in  absence  of  collagen  VI  might  be  ascribed  to  the 
abnormal engagement of integrins, probable binding partners of collagen VI in the extracellular 
matrix.  Mishandling of  Ca2+ by the  SR caused by the  mitochondrial  dysfunctions  would cause 
further increase of the PTP opening, setting in motion the pathomechanism that eventually lead to 
structural defects of both mitochondria and SR. 
More recently, deregulation of the autophagic process has been associated to the pathogenesis 
of the dystrophic phenotype of Col6a1-/- (Grumati et al., 2010). Impaired autophagy in Col6a1-/- 
would cause accumulation of abnormal and dysfunctional organelles and apoptosis of the muscle 
fibers caused by the increased production of reactive oxygen species. Forced induction of autophagy 
is able to prevent this pathological mechanism and protect Col6a1-/- myofibers from degeneration.  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2 - AIM OF THE STUDY
Transcriptome-wide  analysis  using  microarray  and  RNA-Sequencing  (RNA-Seq)  based 
approaches have been widely used to help elucidate molecular mechanisms and pathways active in 
healthy and diseased skeletal muscle, both in animal models and in human samples (Bakay, Zhao, 
Chen, & Hoffman, 2002; Palstra et al., 2013; Porter et al., 2002; Zhou, Dimachkie, Xiong, Tan, & 
Arnett,  2004).  Compared to  microarray,  which  is  a  well  established and relatively  inexpensive 
method allowing for comparative gene expression analysis, RNA-Seq allows to more quantitatively 
assess individual transcripts including splice variants within the transcriptome (Ozsolak & Milos, 
2011). While microarray is based on hybridization of samples to a predetermined number of probes 
designed on a preexisting database, RNA-Seq allows gene expression quantification, and discovery 
of new gene and transcript variants only by directly interrogating the genome of reference without 
the  possible  limitation  of  being  restricted  to  just  transcripts  represented  in  a  single  array. 
Furthermore, RNA-Seq performed at sufficient coverage has a broader dynamic range to detect and 
quantify transcripts that are rare and expressed below the threshold of detection of microarray, while 
also  avoiding  the  interference  from  non-specific  background  signal  resulting  from  cross-
hybridization  in  microarray.  However,  RNA-Seq  is  computationally  very  demanding  and 
necessitates  complex  algorithms  and  bioinformatic  tools  to  address  this  challenge  (Garber, 
Grabherr, Guttman, & Trapnell, 2011).
Microarray  based  analysis  in  limited  numbers  of  unselected  biopsies  from patients  with 
COL6-RD has been reported ,  while RNA-Seq so far has not been performed in biopsies form 
COL6-RD patients (Paco et al., 2013). To further elucidate pathophysiologic pathways involved at 
the different histological states of the disease in larger number of biopsies and to compare the two 
different  approaches  to  expression  profiling,  we  have  utilized  both  microarray  and  RNA-Seq 
platforms in the same set of COL6-RD muscle biopsies and normal controls to characterize the 
progression of COL6-RD as reflected by relative gene expression and transcript patterns. Our study 
shows that different histological stages of COL6-RD are characterized by the same pattern of gene 
expression,  involving  predominantly  the  upregulation  of  genes  coding  for  components  of  the 
extracellular matrix, which is already evident at a histological stage at which there is no prominent 
fibrosis evident yet, and the downregulation of muscle specific genes. Our results also suggest that 
TGFβ1 dependent  pathways  act  as  a  major  drivers  of  the  pathological  changes  at  the  skeletal 
muscle level. Moreover, muscle biopsies from COL6-RD patients are characterized by an increase 
in alternative spliced isoforms of extracellular matrix-related genes that  might contribute to the 
pathogenesis of the disease.  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3 - MATERIALS AND METHODS
3.1 - Participants
We obtained  approval  from the  National  Institute  of  Neurological  Disorders  and  Stroke 
(NINDS) Institutional Review Board for this study. Subjects (and/or parents, for minor under the 
age of 18 years) who agreed to participate provided informed consent. Diagnosis of COL6-RD was 
made by prior clinical assessments including medical history, neuromuscular examinations, muscle 
biopsy  histological  and  immunohistochemical  studies,  and  further  confirmed by  genetic  testing 
(Table 1, at the end of this chapter).
3.2 - Histology and images acquisition
Snap  frozen  muscle  biopsies  were  sectioned  with  a  Thermo Scientific  Microm HM 560 
cryostat (Thermo Scientific, Wilmington, DE). Ten μm thick cryosections were mounted onto glass 
slides. Two type of staining were performed: hematoxylin and eosin (H&E), and Gomori trichrome 
staning (GTC). H&E was performed using a standard protocol. Briefly, sections were incubated for 
1 minute in Harris hematoxylin (VWR, Radnor, PA), washed for 2 minutes in running tap water, 
and incubated in eosin (VWR, Radnor, PA) for 1 minute. The sections were dehydrated in ascending 
alcohol solutions (50%, 70%, 80%, 95%, 100%) cleared in xylene, and mounted with Permount (, 
Fisher Scientific, Pittsburgh, PA). GTC was performed using the Gomori Trichrome Kit (Green 
Collagen)  (  Thermo  Scientific,  Wilmington,  DE).  Images  of  specimens  were  acquired  with 
transmitted-light brightfield using a Zeiss microscope Axio Imager.A2 (Carl Zeiss,  Oberkochen, 
Germany)  and  AxioCam camera  (AxioCam MRc  5;  software  AxioVision  Rel  4.8,  Carl  Zeiss, 
Oberkochen, Germany). 
3.3 - Automated image analysis
To measure  the  cross  sectional  area  of  the  muscle  fibers,  we  propose  a  structured  edge 
detection based hierarchical segmentation algorithm for muscle image segmentation. The structured 
edge detection, which can better capture inherent muscle image edge structures,  is achieved by 
extending a random decision forest framework. The proposed hierarchical segmentation strategy 
can segment out muscle cells exhibiting both strong and weak boundaries.  An overview of our 
proposed muscle image segmentation algorithm is shown in Figure 3.  
 15
Given an image patch, an edge map is generated by the proposed structured edge detection 
algorithm; an Ultrametric Contour Map (UCM) is constructed and a set of segmentation candidates 
is generated by adjusting the thresholds of UCM; and an efficient dynamic programming based 
subset selection algorithm is then used to choose the best regions for muscle image segmentation 
based on a constructed tree graph.
The structured edge detection is achieved by extending a random decision forest framework. 
A decision forest F = {Tt} is an ensemble of decision trees Tt, which are trained independently on 
randomly selected samples S={si=(xi, yi)}, where xi and yi denote the input features and output labels 
of  the  i-th  training  sample,  respectively.  A decision  tree  Tt  produces  the  prediction  results  by 
recursively branching a feature sample x left or right down the tree until a leaf node is reached. For 
a  decision  forest,  the  predictions  Tt(x)  from  individual  trees  are  combined  together  using  an 
ensemble model. Majority voting and averaging are common ensemble choices for classification 
and regression problems, respectively.
During the training of a decision tree, at each node n, a split function h(x) is chosen to split 
the samples Sn into left SnL or right SnR. For multiclass classification, the split  function h(x)  is 
optimized by maximizing the information gain. 
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Figure 3. Overview of the muscle image segmentation algorithm. 
Starting from the captured image, the edge map is built via a structured edge detection algorithm. The Ultrameric Contour Map (UCM) 
that  derives  is  then  subjected  to  a  hierarchical  image  segmentation  algorithm,  which  results  in  the  final  image  containing  the 
segmentation results that will be measured to extrapolate the cross sectional area of the muscle fibers
Where H(Sn) is the class entropy function. 
The split function h(x) can be an arbitrary classifier. A common choice is a stump function 
that  is  found  to  be  computationally  efficient  and  effective  in  practice.  The  training  procedure 
continues to split the samples until either a maximum depth is reached, or too few samples are left, 
or information gain falls below a certain threshold.
Since  a  decision  tree  classifier  generates  the  actual  prediction  at  the  leaf  nodes,  more 
information can be stored at the leaf nodes than class likelihoods. Based on this observation, we 
propose to store edge structure information at  the leaf nodes for structured muscle image edge 
detection. Different from traditional edge detection algorithms, which take an image patch x as an 
input and compute the probability of the edge existence at the center pixel p,  the output of our 
proposed structured edge detection algorithm is an edge mask around the central pixel p instead of 
the likelihood value. After learning the decision tree, the median of the edge masks sent to the leaf 
node will be stored as the leaf node output.
In  general,  the  hierarchical  image segmentation  consists  of  two steps:  1)  a  collection  of 
segmentation candidates is generated by running different segmentation algorithms with varying 
parameters;  2)  Based  on  some  domain-specific  criteria,  the  best  subset  of  the  generated 
segmentation candidates is selected as the final segmentation results. In this work, an Ultrametric 
Contour Map (UCM) is first constructed on the edge map generated by the proposed structured edge 
detection algorithm presented in the previous section, then the pool of segmentation candidates is 
produced by setting different thresholds of UCM. Because of the nice property of UCM where the 
segmentation results using different thresholds are nested into one another, we can construct a tree 
graph for this pool of segmentation candidates.  The final step is  to solve this tree graph based 
MWIS problem using dynamic programming.
Given a set of segmentation candidates generated with different thresholds using UCM, an 
undirected and weighted tree graph, G=(V,E,w), is constructed, where V={vi | i=1,2,…,n} represents 
the nodes with each vi corresponding to a segmented region Ri. The symbol E denotes the edges of 
the graph. The node weight w is learned via a general random decision forest classifier to represent 
the likelihood of Ri as a real muscle cell. An adjacent matrix A={aij |i,j=1,...,n} is then built with 
aij=1 if Ri (Rj) is a subset of Rj (Ri), and otherwise 0. Denote x as the indicator vector, where its 
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In#this#paper,#we#propose#a#structured#edge#detection#based#hierarchical#segmentation#algorithm#for#
muscle#image#segmentation.#The#structured#edge#detection,#which#can#better#capture#inherent#muscle#
image#edge#structures,#is#achieved#by#extending#a#random#decision#forest#framework.#The#proposed#
hierarchical#segmentation#strategy#can#segment#out#muscle#cells#exhibiting#both#strong#and#weak#
boundaries.##
An#overview#of#our#proposed#muscle#image#segmentation#algorithm#is#shown#in#Figure#1.#Given#an#
image#patch,#1)#an#edge#map#is#generated#by#the#proposed#structured#edge#detection#algorithm;#2)#an#
Ultrametric#Contour#Map#(UCM)#is#constructed#and#a#set#of#segmentation#candidates#is#generated#by#
adjusting#the#thresholds#of#UCM;#and#3)#an#efficient#dynamic#programming#based#subset#selection#
algorithm#is#then#used#to#choose#the#best#regions#for#muscle#image#segmentation#based#on#a#
constructed#tree#graph.#
#
Figure'1'An'overview'of'the'proposed'muscle'image'segmentation'algorithm.'
1) Structured#edge#detection#
The#structured#edge#detection#is#achieved#by#extending#a#random#decision#forest#framework.#A#
decision#forest#F'='{Tt}#is#an#ensemble#of#decision#trees#Tt,#which#are#trained#independently#on#
randomly#selected#samples#S={si=(xi,'yi)},#where#xi#and#yi''denote#the#input#features#and#output#
labels#of#the#iCth#training#sample,#respectively.#A#decision#tree#Tt'produces#the#prediction#results#
by#recursively#branching#a#feature#sample#x'left#or#right#down#the#tree#until#a#leaf#node#is#
reached.#For#a#decision#forest,#the#predictions#Tt(x)#from#individual#trees#are#combined#together#
using#an#ensemble#model.#Majority#voting#and#averaging#are#common#ensemble#choices#for#
classification#and#regression#problems,#respectively.#
#
During#the#training#of#a#decision#tree,#at#each#node#n,#a#split#function#h(x)#is#chosen#to#split#the#
samples#Sn#into#left#SnL#or#right#SnR.#For#multiclass#classification,#the#split#function#h(x)#is#
optimized#by#maximizing#the#information#gain#! !! = ! !! − ( !!!!! ! !!! + ! !!!!! ! !!! )#
element is equal to 1 if the corresponding node is selected, otherwise 0. Finally, the constrained 
subset selection problem is formulated as
Considering the special tree graph structure, above equation can be efficiently solved via the 
dynamic programming approach with a bottom-to-up strategy.
To quantify the fibrosis from images taken of the Gomori stain we proceeded as follows. 
Because of staining variations, the intensities of green regions indicating the deposition of collagen 
in  the  extracellular  matrix  might  vary  considerably  across  different  image  regions.  In  order  to 
precisely measure the green region area, for each image, we manually sample a few points from the 
green regions, and we call these samples reference points. During testing stage, we compute the 
intensity differences between each image pixel  and its  reference points.  If  the median of  these 
differences was less than a prefixed threshold, this pixel is counted as “green”.
 After segmentation of green pixels, connected component algorithm is applied to group the 
green  pixels  into  isolated  components.  Those  components  with  too  few pixels  are  counted  as 
“noises” and discarded. The green area of the image is computed as the number of all the kept green 
pixels.
3.4 - RNA Isolation and Quality Assessment
Snap  frozen  muscle  biopsies  were  sectioned  with  a  Thermo Scientific  Microm HM 560 
cryostat (Thermo Scientific, Wilmington, DE). Fifteen 10 μm cryosections were collected in Trizol 
(Life  Technologies,  Carlsbad,  CA).  The  RNA was  isolated  using  standard  Trizol  protocol,  and 
further  purified  using  miRNeasy  Mini  Kit  (Qiagen,  Valencia,  CA).  After  isolation,  the  RNA 
concentration  was  measured  using  a  Nanodrop  2000  spectrophotometer  (Thermo  Scientific, 
Wilmington,  DE).  The  RNA  samples  were  analyzed  using  a  2100  Bioanalyzer  (Agilent 
Technologies,  Santa  Clara,  CA) to  obtain  RNA integrity  numbers  (RIN) as  measure  of  quality 
(Schroeder et al., 2006). Only samples having a RIN quality ≥ 6 were subject to Microarray analysis 
RNA-Seq Analysis. See Table 2 for RNA yield and RIN numbers for these samples.
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Where#H(Sn)#is#the#class#entropy#function.#The#split#function#h(x)#can#be#an#arbitrary#classifier.#A#common#
choice#is#a#stump#function#that#is#found#to#be#computationally#efficient#and#effective#in#practice.#The#
training#procedure#continues#to#split#the#samples#until#either#a#maximum#depth#is#reached,#or#too#few#
samples#are#left,#or#information#gain#falls#below#a#certain#threshold.#
Since#a#decision#tree#classifier#generates#the#actual#prediction#at#the#leaf#nodes,#more#information#can#
be#stored#at#the#leaf#nodes#than#class#likelihoods.#Based#on#this#observation,#we#propose#to#store#edge#
structure#information#at#the#leaf#nodes#for#structured#muscle#image#edge#detection.#Different#from#
traditional#edge#detection#algorithms,#which#take#an#image#patch#x#as#an#input#and#compute#the#
probability#of#the#edge#existence#at#the#center#pixel#p,#the#output#of#our#proposed#structured#edge#
detection#algorithm#is#an#edge#mask#around#the#central#pixel#p#instead#of#the#likelihood#value.#After#
learning#the#decision#tree,#the#median#of#the#edge#masks#sent#to#the#leaf#node#will#be#stored#as#the#leaf#
node#output.#
2) Hierarchical#image#segmentation##
In#general,#the#hierarchical#image#segmentation#consists#of#two#steps:#1)#a#collection#of#
segmentation#candidates#is#generated#by#running#different#segmentation#algorithms#with#
varying#parameters;#2)#Based#on#some#domainSspecific#criteria,#the#best#subset#of#the#generated#
segmentation#candidates#is#selected#as#the#final#segmentation#results.#In#this#work,#an#
Ultrametric#Contour#Map#(UCM)#is#first#constructed#on#the#edge#map#generated#by#the#
proposed#structured#edge#detection#algorithm#presented#in#the#previous#section,#then#the#pool#
of#segmentation#candidates#is#produced#by#setting#different#thresholds#of#UCM.#Because#of#the#
nice#property#of#UCM#where#the#segmentation#results#using#different#thresholds#are#nested#into#
one#another,#we#can#construct#a#tree#graph#for#this#pool#of#segmentation#candidates.#The#final#
step#is#to#solve#this#tree#graph#based#MWIS#problem#using#dynamic#programming.#
#
Given#a#set#of#segmentation#candidates#generated#with#different#thresholds#using#UCM,#an#
undirected#and#weighted#tree#graph,#G=(V,E,w),#is#constructed,#where#V={vi'|'i=1,2,…,n}#
represents#the#nodes#with#each#vi#corresponding#to#a#segmented#region#Ri.#The#symbol'E#
denotes#the#edges#of#the#graph.#The#node#weight#w#is#learned#via#a#general#random#decision#
forest#classifier#to#represent#the#likelihood#of#Ri#as#a#real#muscle#cell.#An#adjacent#matrix'A={aij'
|i,j=1,...,n}'is#then#built#with#aij=1#if#Ri'(Rj)#is#a#subset#of#Rj'(Ri),#and#otherwise#0.#Denote#x#as#the#
indicator#vector,#where#its#element#is#equal#to#1#if#the#corresponding#node#is#selected,#otherwise#
0.#Finally,#the#constrained#subset#selection#problem#is#formulated#as#x∗ = !argmaxx !!x !!!!such%that!x! + x! ≤ 1!if!!!" = 1!#
Considering#the#special#tree#graph#structure,#above#equation#can#be#efficiently#solved#via#the#
dynamic#programming#approach#with#a#bottomStoSup#strategy.#
3.5 - Microarray Analysis 
Labeled  cRNA libraries  were  prepared  from isolated  total  RNA according  to  Illumina 
protocols (Illumina, Inc, San Diego, CA).   For RNA labeling, 500 ng of total RNA was used in 
conjunction with the Illumina recommended protocol for hybridization to the HumanHT-12 v4.0 
Expression  BeadChip.    After  washing  and  staining,  BeadChips  were  then  scanned  using  the 
Illumina BeadArray Reader. Where after, the Illumina GenomeStudio Gene Expression Module was 
used to generate summarized expression measurements per gene represented on the BeadChip.  This 
expression  data  was  then  import  into  R  (http://cran.r-project.org/),  Log2  transformed,  quantile 
normalized,  then  quality  inspected  via  Tukey  box  plot,  covariance-based  Principal  Component 
Analysis  (PCA)  scatter  plot,  and  correlation-based  Heat  Map.  Post  quality  inspection,  the 
coefficient of variation (CV) and mean expression for each gene was calculated by sample class 
then modeled using locally weighted scatter plot smoothing (CV ~ mean). Resulting model fits were 
then inspected  and used to  define "system noise"  as  the  mean expression value  across  sample 
classes at which the linear relationship between CV (i.e., noise) and mean expression (i.e., signal) is 
grossly lost. Genes not having at least one normalized value (Quantile(Log2(RPKM+2))) greater 
than "system noise" were discarded as noise-biased. While, normalized values for remaining genes 
were  floored  to  equal  "system  noise"  if  less  than  "system  noise".  To  identify  differences  in 
normalized values (i.e., gene expression) between CMD samples and Control samples, the Welch-
modified t-test was applied under Benjamin–Hochberg (BH) False-Discovery Rate (FDR) Multiple 
Comparison Correction (MCC) condition. Such that, genes with a corrected P < 0.05 by this test and 
an absolute fold-difference ≥ 1.5X between class means were those considered to be differentially 
expressed between CMD and Control. Annotations for these genes were obtained from IPA (http://
www.ingenuity.com/). Where after, IPA was used again to determine what biological functions and 
pathways are enriched for these genes;  along with what networks of genes they have the most 
connectivity with. Comparison and intersection of results with those obtained by RNA-Seq Analysis 
was accomplished using the IPA-assigned gene symbol.
3.6 - RNA-Seq Analysis 
cDNA libraries were prepared from isolated RNA according to Illumina protocols (Illumina, 
Inc,  San Diego,  CA) and sequenced by Beckman Coulter  Genomics  (Danvers,  Massachusetts). 
Briefly, mRNA libraries were constructed from 150 ng of total RNA using the Illumina TruSeq 
RNA Sample Prep Kits, version 2.   The resulting cDNA was fragmented using a Covaris E210. 
Library amplification was performed using 12-15 cycles to minimize the risk of over-amplification.  
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Unique barcode adapters were applied to each library.   Equal volumes of individual libraries were 
pool and run on a MiSeq.   The libraries were then repooled based on the MiSeq demultiplexing 
results and sequenced on a HiSeq 2000 with ver 3 flow cells and sequencing reagents.  On average, 
69 million 100-base read pairs were generated for each individual library.    Data was processed 
using RTA 1.13.48 and deplexed via CASAVA 1.8.2.  Post deplexing, resulting .fastq files were 
trimmed  to  remove  3'  occurring  adaptor  sequences  using  the  FASTQ/A Clipper  tool  (http://
hannonlab.cshl.edu).    Adaptor trimmed .fastq files were then import into the CLCbio Genomics 
Workbench (www.clcbio.com) for quality inspection, quality trimming, filtering, and mapping. Per 
quality trimming, 15bp from the 5' end of each read for each sample was globally removed along 
with 1bp from the 3' end. Bases with a call accuracy < 95% were also removed. Per filtering, read 
pairs having more than two ambiguities in at least one read were discarded along with pairs < 15bp 
in length. Per mapping, the "RNA-Seq" tool was used under default parameters to align reads in 
pairs  to the human genome (hg19).  Post  mapping,  the number of  aligned reads falling in each 
annotated "gene" were enumerated then converted into number of "Reads Per Kilo base of transcript 
Million  mapped  reads"  ("RPKM").  RPKM  values  were  then  import  into  R  (http://www.r-
project.org/), pedestalled by 2 (RPKM+2), log (base 2) transformed (Log2(RPKM+2), and filtered 
to  remove  genes  not  having  a  transformed  value  >1  for  at  least  one  sample.  Post  filtering, 
transformed values for remaining genes were quantile normalized (Quantile(Log2(RPKM+2))) then 
quality inspected via Tukey box plot, covariance-based principal component analysis (PCA) scatter 
plot, and correlation-based Heat map. Post quality inspection, the coefficient of variation (CV) and 
mean expression for each gene was calculated by sample class then modeled via locally weighted 
scatter plot smoothing (CV ~ mean). Resulting model fits were then inspected and used to define 
"system noise" as the mean expression value across sample classes at which the linear relationship 
between CV (i.e., noise) and mean expression (i.e., signal) is grossly lost. Genes not having at least 
one normalized value (Quantile(Log2(RPKM+2))) greater than "system noise" were discarded as 
noise-biased. While, normalized values for remaining genes were floored to equal "system noise" if 
less  than  "system  noise".  To  identify  differences  in  normalized  values  (i.e.,  gene  expression) 
between CMD and Control, the Welch-modified t-test was applied under Benjamin–Hochberg (BH) 
False-Discovery Rate (FDR) Multiple Comparison Correction (MCC) condition. Such that, genes 
with a corrected P < 0.05 by this test and an absolute fold-difference >= 1.5X between class means 
were those considered to be differentially expressed between CMD and Control. Annotations for 
these genes were obtained from IPA (http://www.ingenuity.com/). Where after, IPA was used again 
to determine what biological functions and pathways are enriched for these genes; along with what 
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networks of genes they have the most connectivity with. Comparison and intersection of results 
with those obtained by Microarray Analysis was accomplished using the IPA-assigned gene symbol. 
Finally, the same methods described were repeated using "transcript-level" enumerations in place of 
"gene-level"  enumerations;  providing  for  a  list  of  differentially  expressed  transcripts  occurring 
between CMD and control. 
3.7 - qRT-PCR expression validation
We synthesized cDNA from 300 ng of total RNA using the pScript XLT cDNA SuperMix 
(Quanta Biosciences, Gaithersburg, MD). We measured cDNA abundance using Sybr Green on an 
Applied  Biosystems  QuantStudio  6  qRT-PCR  system  (Life  Technologies,  Carlsbad,  CA).  We 
performed serial dilutions of cDNA to find primer pairs with 100% efficiency and a single product 
on the dissociation curve. We used TBP as a normalization gene. Primer pairs are listed in Table 3. 
As biological replicates, we used 6 COL6-RD samples and 5 control samples. All the experiments 
were  conducted  in  triplicates.  Fold-change  was  assessed  determining  the  ΔΔCt  between  the 
normalization gene and the target gene.
3.8 - Immunoblotting
Snap  frozen  muscle  biopsies  were  sectioned  with  a  Thermo Scientific  Microm HM 560 
cryostat (Thermo Scientific, Wilmington, DE). Twenty-to-thirty 10 μm cryosections were collected 
and mechanically disrupted and lysed in 100 μl of NP40 lysis buffer (1M Tris-HCl pH 7.4, 1.5M 
NaCl, 0.5M EDTA pH 7.4, 1% NP40) with protease inhibitors (chymostatin, leupeptin, pepstatin A, 
antipain) and phosphatase inhibitors (Phostop, Roche, Mannheim, Germany). The cell extracts were 
centrifuged for 15 minutes at  14,000 g at  4 ºC. Protein concentration was assessed using BCA 
protein assay kit (Millipore, Billerica, MA). Thirty μg of total protein was separated in NuPage 
4-12% Bis-Tris  gel  (Life Technologies,  Carlsbad,  CA) and transferred on PVDF membrane for 
probing. The primary antibodies were used at the dilution of 1:1000. The primary antibodies used 
were: THBS4 (AF2390, R&D Systems, Minneapolis, MN), BECN1 (3738, Cell Signaling, Danvers, 
MA),  LC3B (3868,  Cell  Signaling,  Danvers,  MA),  DCN (AF143,  R&D Systems,  Minneapolis, 
MN), BGN (LF-51, kindly provided by Dr. Larry Fisher, NIDCR/NIH), Phospho-Smad2 (3101, 
Cell Signaling, Danvers, MA), Smad2 (5339, Cell Signaling, Danvers, MA ). Bound antibodies 
were  detected  with  the  appropriate  secondary  antibodies  HRP-conjugated.  The  results  were 
normalized to GAPDH (MAB374, Millipore, Billerica, MA).  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Patients Mutation
ID Sex Gene Exon cDNA Protein Effect
UC179 M COL6A1 14 c.1057+1G>A Intronic Splice Site Mutation
UC21 M COL6A3 16 c.6610+2T>del Intronic Splice Site Mutation
UC397.1 F
COL6A1 1 c.46T>C p.Trp16Arg Uncertain
COL6A1 19 c.1290_1291delAG p.Gly431ThrfsX16 Frame shift
UC264 M COL6A2 6 c.813G>A p.Gly271Asp Triple Helical Domain
UC220 M
COL6A2 24 c.1771-25A>G Intronic Splice Site Mutation
COL6A2 26 c.1970-9G>A Intronic Splice Site Mutation
UC51 M COL6A2 28 c.2793_2821del29 p.Ser931_940del Frame shift
UC222 F
COL6A2 6 C.856-3C>G Intronic Splice Site Mutation
COL6A2 26 c.2386A>T p.Lys796Stop Premature Stop Codon
UC13 M
COL6A2 26 c.2170C>T p.Arg724Cys Uncertain
COL6A2 26 c.2411T>G p.Val804Gly Uncertain
COL6A3 15 c.6156+1G>A Intronic Splice Site Mutation
UC30 M COL6A1 13 c.1002+1G>A Intronic Splice Site Mutation
UC99 F COL6A1 11 c.904-1G>C Intronic Splice Site Mutation
UC95 F COL6A3 17 c.6229G>C p.Gly2077Arg Triple Helical Domain
UC338 M
COL6A2 26 c.2197G>A p.Gly733Arg Triple Helical Domain
COL6A2 28 c.2917G>A p.Val973Met Uncertain
UC100 M COL6A3 16 c.6610+1G>A Intronic Splice Site Mutation
UC54 F COL6A3 16 c.6610+1G>A Intronic Splice Site Mutation
UC56 F COL6A3 18 c.6408+9C>G p.Arg2136_Gly2137ins3 Splice Site Mutation
UC384 M
COL6A1 10 c.877G>A p.Gly293Arg Triple Helical Domain
COL6A1 10 c.859-10A>G Intronic Uncertain
UC43 M
COL6A2 26 c.1970-3C>A Intronic Splice Site Mutation
COL6A2 9 c.954+20_+55del36 Uncertain Uncertain
UC98 M COL6A1 21 c.1451C>del Uncertain Frame shift
UC50 M COL6A3 15 c.6156+2T>C Intronic Splice Site Mutation
UC129 M COL6A3 15 c6156+1G>A Intronic Splice Site Mutation
UC77 M COL6A1 12 c.957+1G>A Intronic Splice Site Mutation
UC357 F COL6A2 10 c.954_955ins11 Intronic Splice Site Mutation
 1
Table 1. COL6RD sample identification code and corresponding cDNA and protein pathogenic mutations.
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Sample ID Concentration (ng/ μl) RIN Sample ID Concentration (ng/ μl) RIN
M13-1 140.7 8.2 UC220 204.0 8.5
M13-7 113.5 8.4 UC51 63.6 8.3
M13-16 117.7 7.3 UC222 65.0 8.3
M13-18 83.5 7.2 UC13 124.6 8.2
M13-23 68.9 7.1 UC30 86.6 7.9
M13-25 60.5 7.1 UC99 162.5 8.7
M13-30 93.8 8.3 UC95 97.9 7.4
M13-33 156.5 8.2 UC338 62.8 7.3
M13-35 87.8 7.7 UC100 184.9 8.9
M13-40 75.8 7.1 UC54 95.5 7.9
M13-43 133.5 8.1 UC56 104.3 7.5
M13-45 67.3 7.6 UC384 108.8 8.4
M13-47 112.9 7.3 UC43 126.1 7.10
M13-49 140.6 8 UC98 61.4 7.8
UC179 104.9 8 UC50 92.3 7.7
UC21 139.0 9 UC129 141.9 8.3
UC397.1 60.2 7.8 UC77 54.0 7.8
UC264 91.5 8.4 UC357 81.4 7.7
 1
Table 2. Controls (M) and COL6-RD (UC) samples with respective RNA concentration (ng/μl) and quality assessment based on 
the RNA Integrity Number (RIN).
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Gene Symbol Forward Primer Reverse Primer
THBS4 CTTGCGGTCCTCTCAAGTTT CGGGTAGCAGGGATGGTATT
TGFB1 TGGAAACCCACAACGAAATCT GTATCGCCAGGAATTGTTGCT
COL1A2 TGAAGATGGTCACCCTGGAA CCCCTAATGCCTTTGAAGCC
COL3A1 TCAAGGGTGAAAGTGGGAAAC CACGATCACCCTTGCCAC
CTGF GGAAGAGAACATTAAGAAGGGCA CCGTCGGTACATACTCCACA
BGN CAGCACCTCTACGCCCTC GCAGTTCATGTTCCGGAGC
FN1 AGTCTTTACCACACTGCAGC ACAACGATGCTTCCTGAGTC
ATROGIN1 ACCAAAACTCAGTATTTCCACCA AAAGGCAGGTCAGTGAAGGT
BECLIN1 CAGGAGGAAGCTCAGTATCAGA TTGTGCCAAACTGTCCACTG
BNIP3 TCTTTAAACACCCGAAGCGC CGCCTTCCAATATAGATCCCC
TP53 GTTTCCGTCTGGGCTTCT ACCTCAGGCGGCTCATAG
CDK1N CAGACCAGCATGACAGATTTCT CGGCCAGGGTATGTACATGA
CILP ACCCACATCTACCTCTTGCC CACTCACCAGGGCTCTCC
MGP AGCCTGATCCTTCTTGCCAT CGTTCTCGGATCCTCTCTTG
LUM CCTTCTGGTCTCCCTGTCTC GATCCAGCTCAACCAGGGAT
MYH1 CGTCAGTCAAGGGGAGATCA TTGTCAGCAACTTCAGTGCC
TBP CCGAATATAATCCCAAGCGGTT GCTCCTGTGCACACCATTTT
 1
Table 3. Primers used for qRT-PCR analyses.
4 - RESULTS
4.1 - Morphological characterization
In order to assign histological stages of severity to the biopsies included in the molecular 
analysis we first performed a basic histological review of the samples.
Twenty  two  snap-frozen  COL6RD  skeletal  muscle  biopsies  were  analyzed  using  basic 
histology staining: hematoxylin and eosin (H&E) and Gömöri trichrome staining (GTC). Fifteen 
patients were males, seven were female. All of the patients whose muscle biopsies were studied 
have a genetically confirmed diagnosis of collagen VI-related dystrophy with pathogenic mutations 
occurring in one of the three genes coding for collagen type VI (COL6A1, COL6A2, COL6A3)
(Table  1).  Fifteen  patients  carried  de  novo  dominant  mutations,  while  7  of  the  patients  have 
recessively inherited mutations. The mutations were distributed as follow: 31% on COL6A1, 44% 
on COL6A2, 25% on COL6A3. We arbitrarily formed three groups based on the severity of the 
histological  changes.  The  first  group,  COL6RD-1,  was  characterized  by  very  mild  histological 
changes, mainly represented by muscle fiber atrophy; the second group, COL6RD-2, was defined by 
muscle fiber atrophy and moderate fibrosis. Fibrosis was defined moderate when 40%-60% of the 
individual muscle fibers were surrounded by a rim of connective tissue identified by the color blue 
in the GTC stain, with overall preservation of the skeletal muscle architecture. The third group, 
COL6RD-3, was defined by muscle fiber atrophy, severe fibrosis, and fat infiltration. Fibrosis was 
considered  severe  when  more  than  60%  of  the  individual  muscle  fibers  were  surrounded  by 
connective tissue, together with skeletal muscle architecture disruption. We visually assigned the 
muscle  biopsies  to  any  of  these  groups  and  we  used  the  automated  image  analysis  algorithm 
described in the methods to quantify cross sectional area and fibrosis. The reduction in the cross 
sectional area of the muscle fibers was evident and statistically significant in all of the three groups 
compared to normal controls. We also noted a change in the fiber size distribution between controls 
and COL6RD muscle biopsies. The patients muscle samples had a prevalence of muscle fibers with 
cross sectional area smaller than 1000 μm2, while the normal controls had a prevalence of muscle 
fibers with cross sectional area between 1000 μm2 and 2000 μm2. The quantification of connective 
tissue also followed exactly the way we assigned the patients muscle biopsies to the three groups. 
As expected, COL6RD muscle biopsies showed higher amount of connective tissue when compared 
to normal controls, increasing proceeding from COL6RD-1, COL6RD-2, to COL6RD-3. Results 
are shown in Figure 4. 
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Figure 4. Representative histochemical stains of frozen muscle sections. 
We used Hematoxylin & Eosin and Gomori Trichrome staining to visualize basic histology features such as muscle fiber atrophy, and 
connective tissue deposition, that allowed us to group the patient samples into three groups according to the severity of the muscle 
histology: COL6RD-1,2,3. Quantification of cross sectional area/ fiber size, amount of connective tissue, and distribution of fiber size 
according to the grouping system is shown on the lower panel. The values are expressed as mean ± S.E.M. The statistical significance 
was established using the non-parametric Mann-Whitney test. * indicates p-value < 0.05; *** indicates p-values < 0.0001 when 
compared to the control group. # indicates p-value < 0.0001 when compared to COL6RD-1 group. Scale bar corresponds to 100 μm 
4.2 - Differential gene expression analysis
We next asked whether the relative severity of histological changes in the three groups could 
be correlated to specific patterns of differential gene expression in order to investigate whether there 
were  different  molecular  signatures  evident  at  different  stages  of  the  disease  process.  We used 
microarray-based gene expression profiling and RNA-Seq to compare the transcriptome of the 22 
COL6RD muscle biopsies against 15 aged-matched controls. 
Row  gene  expression  data  from microarray  analysis  were  normalized  and  low  intensity 
values below the noise threshold were filtered out. After filtering, microarray analysis resulted in 
11,172 gene probes present at least in one sample with an expression value greater than the noise 
threshold, corresponding to a total of 8234 human annotated genes. Of these, 648 were differentially 
regulated between normal controls and COL6RD muscle biopsies, with absolute expression level of 
1.5-fold  or  greater  and  p-value  <  0.05.  Of  these,  479  differentially  regulated  genes  were 
upregulated, while 169 were downregulated.
RNA-Seq generated an average of 50 million reads per samples. Quality inspection of the 
reads showed an expected per-sample GC content peak around 60%, ambiguity base content at 
nearly 0%, and average PHRED score near 40 across all the samples, which is indicative of the high 
quality of the sequencing. Filtering and trimming of the reads were uniform throughout the samples 
and, most importantly, preserved 70-80% of the total reads sequenced. Moreover, 99% of the post-
trimmed and filtered reads were successfully mapped to the human genome. After trimming and 
filtering,  RNA-Seq  identified  2889  human  annotated  genes.  Statistical  significance  testing 
determined that a total of 248 genes were differentially expressed between control and COL6RD 
muscle biopsies, with absolute expression level of 1.5-fold or greater and p-value < 0.05. Of these, 
170 differentially regulated genes were upregulated, while 78 were downregulated. 
Only 138 differentially regulated genes were commonly detected by microarray and RNA-
Seq. For these, there was good concordance in direction (R2=1) and magnitude (R2=0.84) of the fold 
change (Figure 5c). 
Hierarchical  heat  maps and Principal  Component Analysis (PCA) were obtained for both 
microarray  and  RNA-Seq.  Analysis  of  the  hierarchical  heat  map  and  the  PCA allowed  the 
identification  of  unique  gene  expression  patterns  clearly  differentiating  controls  and  COL6RD 
muscle biopsies (Figure 5a,  b).  However,  no clear distinction was evident within the COL6RD 
muscle biopsies correlating with the morphological groups the muscle biopsies had previously been 
assigned to.  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Figure 5. Summary of the microarray and RNA-seq findings. 
Panel a and b show post significance analysis hierarchical heat map obtain from microarray (a) and RNA-Seq (b) gene expression 
profiling. Principal component analysis of the gene expression levels obtain by microarray and RNA-Seq is also shown. The two PCA 
analyses show clearly that the controls cluster together and segregate from the COL6RD samples. However, there is no clear clustering 
of the COL6RD samples by histology groups, as they are all scattered and mixed. Panel c shows Venn diagram showing the total 
number of differentially regulated genes (p-value <0.05; Fold change magnitude = 1.5) obtained from either microarray or RNA-Seq 
platforms. In the central part are the dysregulated genes identifies by both techniques. On the right, comparison of direction and fold 
change of the differentially regulated genes commonly detected by microarray and RNA-Seq. The plot shows a high concordance of 
direction (R2=1) and magnitude (R2=0.84)
We next  more  closely  analyzed  all  the  genes  that  were  differentially  regulated  in  either 
microarray or RNA-Seq gene expression analyses. We combined the list of differentially regulated 
genes produced by microarray and RNA-seq in a global gene list of uniquely occurring genes. For 
each  gene  we  considered  only  the  highest  value  of  expression.  This  process  generated  758 
differentially regulated genes which were submitted to the web-based Database for  Annotation, 
Visualization and Integrated Discovery (DAVID) for gene ontology analysis. Ranked by p-value 
and gene count,  the upregulated genes were most  commonly represented by the gene ontology 
terms extracellular matrix (p-value=6.18E-38, gene count=69), proteinaceous extracellular matrix 
(p-value=4.46E-36, gene count= 65), extracellular region part (p-value=1.66E-30, gene count=100), 
and extracellular region (p-value=7.68E-23, gene count=7.68). In contrast, the downregulated genes 
were represented by the gene ontology terms mitochondrion (p-value=3.11E-14, gene count=53), 
generation  of  precursor  metabolites  and  energy  (p-value=2.16E-12,  gene  count=27),  glucose 
metabolic  process  (p-value=1.91E-10,  gene  count=18),  and  myofibril  (p-value=1.25E-09,  gene 
count=15) (Table 4). 
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Upregulated Genes Downregulated Genes
Gene Ontology Term Gene Count p-value Gene Ontology Term Gene Count p-value
Extracellular matrix 69 6.18E-38 Mitochondrion 53 3.11E-14
Proteinaceous extracellular matrix 65 4.46E-36 Generation of precursor metabolites and energy 27 2.16E-12
Extracellular region part 100 1.66E-30 Glucose metabolic process 18 1.91E-10
Extracellular region 135 7.68E-23 Myofibril 15 1.25E-09
Extracellular matrix part 31 1.46E-20 Mitochondrial part 32 1.50E-09
Cell adhesion 65 1.04E-18 Contractile fiber part 15 1.58E-09
Biological adhesion 65 1.12E-18 Sarcomere 14 2.64E-09
Extracellular matrix organization 27 1.36E-18 Contractile fiber 15 3.93E-09
Glycosaminoglycan binding 29 4.10E-17 Hexose metabolic process 18 6.51E-09
Extracellular matrix structural constituent 23 4.25E-16 Monosaccharide metabolic process 19 9.28E-09
Pattern binding 29 6.62E-16 Muscle contraction 16 1.31E-08
Polysaccharide binding 29 6.62E-16 Energy derivation by oxidation of organic compounds 15 4.53E-08
Structural molecule activity 57 1.46E-15 Muscle system process 16 4.66E-08
Extracellular structure organization 29 2.50E-15 Striated muscle contraction 9 4.31E-07
Growth factor binding 23 4.14E-14 Glycogen metabolic process 8 8.57E-07
 1
Table 4. Gene ontology analysis.
Gene ontology analysis using DAVID (Huang da, Sherman, & Lempicki, 2009a, 2009b) performed on the list of differentially 
regulated genes obtained from the combination of the uniquely occurring genes from microarray and RNA-Seq data. Of the 758 
differentially regulated gene, 711 were accepted for gene ontology analysis. Here, we show the top 30 gene ontology categories, 
classified by p-value. The most represented term for the upregulated gene is related to the extracellular matrix biogenesis and 
remodeling. The downregulated genes predominantly relate to skeletal muscle structure and function (i.e. muscle organ development, 
contractile fiber part), energy production, and metabolism.
We next evaluated the gene expression differences between controls and COL6RD muscle 
biopsies  considering predicted cellular  localization and molecular  function.  Again,  in  COL6RD 
muscle  biopsies  we  found  that  a  disproportionate  number  of  the  upregulated  gene  products  is 
predicted to be localized in the extracellular matrix (117 upregulated genes vs 5 downregulated 
genes),  plasma membrane  (86  upregulated  genes  vs  33  downregulated  genes)  and  nucleus  (71 
upregulated genes vs 35 downregulated genes) (Figure 6 a). 
Using the same combined gene list (microarray and RNAseq-based) sorted by magnitude of 
the gene expression level we identified thrombospondin 4 (THBS4) as the single gene with the 
greatest difference between COL6RD and control muscle biopsies (fold-change = 17.28; corrected 
p-value = 2.59E-09). Among the 20 highest upregulated genes there were also 4 genes annotated to 
be involved in cartilage and bone formation, namely CILP1, MGP, LUM, and ASPN. Among the 
twenty most upregulated genes were also find CTGF, COL3A1, and COL1A2, which are associated 
with connective tissue deposition and, ultimately, with fibrosis (Figure 6 b). 
Using Ingenuity Pathway Analysis, we searched for cellular function annotations enriched in 
the dataset, considering both upregulated and downregulated genes. We considered only annotations 
with z-score >2 or <-2, and p-value <0.05. Based on z-score and p-value, the cellular function 
annotations  predicted  to  be  increased  in  COL6RD  muscle  biopsies  were  cell  movement  (z-
score=3.342,  p-value=1.64E-20),  migration  of  cells  (z-score=3.135p-value=7.23E-20),  leukocyte 
migration  (z-score=3.093,  p-value=1.12E-06).  The  cellular  function  annotations  predicted  to  be 
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Figure 6. Cellular Distribution of the differentially regulated genes obtained by the combination of microarray and RNA-Seq 
data. 
Panel a shows cellular localization of up- and downregulated genes in COL6RD vs controls. The plot shows how there are more 
upregulated than downregulated genes. The majority of the upregulated genes are related to the extracellular matrix and the plasma 
membrane. Panel b shows the top 20 changing genes listed according to fold-change and color-coded according to their cellular 
localization.
decreased are concentration of ATP (z-score=-2.178, p-value=1.97E-04) and colony formation of 
tumor cell lines (z-score=-2.470, p-value=1.23E-06) (Table 5).
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4.3 - Differentially expressed splice isoforms analysis 
We used the list of differentially regulated genes generated uniquely from the RNA-Seq to 
determine  differences  in  the  expression  of  well  annotated  splice  isoforms  (i.e.  differences  in 
transcript  originating  from the  same gene).  We detected  more  than one  differentially  regulated 
splice isoform for 43 of  the 248 differentially expressed genes.  The number of  different  splice 
isoforms  per  gene  was  highly  variable  and  ranging  from  2-to-12  transcripts  per  gene,  with 
DECORIN showing 12 differentially  regulated splice isoforms.  We submitted the transcripts  to 
Ensemble Database for better characterization. We found that about 61% of the splice isoforms 
were protein coding (77/126), while 39% of the detected differentially expressed splice isoform was 
non protein  coding.  This  non coding portion was further  subdivided in  isoforms that  were not 
coding  for  protein  because  of  retained  introns  (22%),  and  nonsense  mediated  decay  (8.7%). 
However, the remaining 7.1% of non coding transcripts was still processed by the cell, even if they 
would not result in any protein product (Figure 7). 
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Figure 7. Splice variants differentially expressed in COL6RD. 
We show the differentially regulated genes that have more than one splice variant significantly differentially regulated in COL6RD 
compared to normal controls, and the number of transcript per gene. Each bar is proportionally color-coded according to the predicted 
function of the splice variants represented.
We next  performed gene ontology analysis  on the 43 represented genes  with  differential 
splice  isoform  expression.  The  upregulated  splice  isoforms  were  enriched  in  terms  related  to 
extracellular matrix biogenesis, and structural molecule activity. The downregulated splice isoforms 
were related to skeletal muscle function and structure (Table 6).
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Upregulated Downregulated
Gene Ontology Term Gene Count p-value Gene Ontology Term Gene Count p-value
Structural molecule activity 11 2.73E-08 Myofibril 7 2.79E-09
Response to wounding 7 2.01E-04 Contractile fiber 7 4.71E-09
Structural constituent of cytoskeleton 4 2.53E-04 Sarcomere 6 9.77E-08
Focal adhesion 6 2.81E-04 Contractile fiber part 6 2.00E-07
Cellular component morphogenesis 6 4.61E-04 I band 4 4.06E-05
Acute inflammatory response 4 5.88E-04 Actin cytoskeleton 5 2.86E-04
Extracellular region part 8 6.01E-04 Regulation of system process 5 6.34E-04
Translational elongation 4 6.42E-04 Actin binding 5 7.17E-04
Cell morphogenesis involved in 
differentiation 5 6.98E-04 Muscle contraction 4 1.02E-03
Extracellular matrix part 4 8.81E-04 Structural molecule activity 6 1.04E-03
Proteinaceous extracellular matrix 5 1.65E-03 Muscle system process 4 1.34E-03
ECM-receptor interaction 4 2.09E-03 Striated muscle contraction 3 1.67E-03
Extracellular matrix 5 2.17E-03 Striated muscle cell development 3 2.13E-03
Extracellular region 10 2.80E-03 Muscle cell development 3 2.47E-03
Cell morphogenesis 5 2.81E-03 Muscle organ development 4 2.57E-03
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Table 6. Gene ontology analysis on the splice variants. 
Gene ontology analysis using DAVID performed on the genes having >2 differentially regulated splice variants in COL6RD vs 
controls. Of the 46 genes submitted to DAVID, 43 were accepted for gene ontology analysis. Here we show the top 30 gene ontology 
categories, classified by p-value. The most represented categories are related to skeletal muscle function, myofiber organization, 
morphology, and differentiation.
4.4 - Upstream Regulators
We used Upstream Regulator Analysis, a tool available in Ingenuity Pathway Analysis (IPA), 
to predict possible upstream regulators responsible for modulating the genes differentially regulated 
in COL6RD muscle biopsy samples. We considered only the upstream regulators with a z-score > 2 
or <-2, and a p-value < 0.05. Based on the differentially expressed genes present in our dataset, 
TGFβ1 was most  commonly identified regulator predicted as activated (p-value = 6.48E-18; z-
score= 5.627),  applying to  the  regulation of  47 downstream effectors  genes,  all  of  them being 
upregulated in COL6RD muscle biopsies. In the same list we also found downstream targets of 
TGFβ1 that in turn become regulators of other distinct subset of genes, such as CTGF (p-value = 
1.77E-05; z-score= 2.402), indicating a multilevel complexity in the gene regulation specific to our 
cohort of COL6RD.
Among the upstream regulators predicted to be inhibited are estrogen receptor (ESR, p-value 
= 1.38E-15; z-score= -4.062),  the transcription regulator SPDEF (p-value = 6.24E-14; z-score= 
-3.935), and the growth factor WISP2 (p-value = 2.91E-08; z-score= -2.714) (Table 7).  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Upstream Regulator p-value Activation z-score Activation State Upstream Regulator p-value
Activation z-
score Activation State
TGFB1 6.48E-18 5.627 Activated HDAC6 7.63E-07 2.157 Activated
ERK 6.21E-06 3.553 Activated PGR 1.30E-08 2.116 Activated
ERBB2 1.78E-07 3.313 Activated EGFR 1.71E-04 2.109 Activated
SYVN1 2.29E-07 3.298 Activated IL5 9.10E-02 2.000 Activated
P38 MAPK 3.25E-07 3.146 Activated RLIM 1.75E-04 2.000 Activated
PDGF BB 1.41E-12 3.112 Activated SMARCD3 1.59E-03 2.000 Activated
Jnk 5.30E-04 2.765 Activated MAP3K14 1.87E-02 2.000 Activated
GLI1 3.24E-08 2.746 Activated TAZ 5.14E-05 2.000 Activated
Pkc(s) 2.87E-04 2.574 Activated NEDD9 6.69E-03 2.000 Activated
HIF1A 4.18E-10 2.552 Activated RBPJ 2.00E-03 -2.000 Inhibited
CCL5 3.11E-03 2.449 Activated MAP3K7 2.88E-02 -2.000 Inhibited
RELA 1.11E-02 2.425 Activated miR-29b-3p 2.38E-03 -2.219 Inhibited
PRKCD 1.35E-03 2.414 Activated Hdac 3.57E-05 -2.273 Inhibited
CTGF 1.77E-05 2.402 Activated COL18A1 1.08E-04 -2.538 Inhibited
TWIST1 3.13E-04 2.236 Activated WISP2 2.91E-08 -2.714 Inhibited
EIF2AK2 4.87E-02 2.236 Activated FBN1 2.75E-09 -2.797 Inhibited
MYB 1.20E-04 2.215 Activated FOXA1 1.08E-04 -2.802 Inhibited
Akt 3.52E-03 2.213 Activated IgG 2.25E-06 -3.500 Inhibited
TWIST2 1.26E-04 2.207 Activated MGEA5 1.30E-13 -3.550 Inhibited
CSF2 1.62E-01 2.200 Activated SPDEF 6.24E-14 -3.935 Inhibited
LDL 8.56E-03 2.186 Activated Estrogen Receptor 1.38E-15 -4.062 Inhibited
 1
Table 7. Upstream regulator analysis. 
Upstream regulator analysis performed on the list of differentially regulated genes obtained from the combination of the uniquely 
occurring genes from microarray and RNA-Seq. We show the top 30 activated upstream regulators, classified by p-value and z-score, 
and the top 12 inhibited upstream regulators. 
4.5 - Validation of differentially expressed genes by qRT-PCR
We performed technical validation using quantitative reverse transcription-PCR (qRT-PCR) 
in order to validate expression level of selected entries among the most upregulated genes and to 
validate the involvement of specific molecular pathways of interest. We selected a series of 16 target 
genes (BECN1, CILP, COL1A2, COL3A1, CTGF, FN1, LUM, MGP, MYH1, P21/CDKN1A, TGFβ1, 
THBS4,  BGN,  TP53,  ATROGIN1/MAFBX1,  BNIP3)  and  one  reference  gene  that  showed  low 
variance and was not differentially expressed between COL6RD and controls (TBP). We found high 
agreement between the relative gene expression levels measured with microarray and RNA-Seq, 
and qRT-PCR for all of the genes tested. However, the magnitude of the expression level between 
COL6RD  and  controls  samples  measured  with  qRT-PCR  was  always  more  pronounced.  We 
confirmed  the  regulation  of  TGFβ1  pathway  at  the  transcriptional  level,  with  the  increased 
expression  of  COL1A2,  COL3A1,CTGF,  FN1,  and  BGN.  mRNA  level  of  TGFβ1  resulted 
significantly increased when measured with qRT-PCR only. The upregulation of cartilage and bone 
formation related genes (CILP, MGP, LUM) was also confirmed. We explored further the autophagy 
pathway by measuring BECN1 and BNIP3, key initiators of the autophagy process. The expression 
levels of BECN1 and BNIP3 were not different between controls and COL6RD muscle biopsies. We 
also confirmed that ATROGIN1,  the E3 ubiquitin ligase involved in the FOXO3-driven atrophy 
program in skeletal muscle, was transcriptionally repressed (Figure 8).  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Figure 8. qRT-PCR technical validation.
Technical validation performed by qPCR on 16 genes performed on a random selection of n=5 controls (30%) and n=6 COL6RD 
(27%) muscle biopsies, accompanied by the post-noise filtering expression levels for the same samples detected by RNA-Seq and 
microarray. The relative expression levels are plotted on the y-axis ± S.E.M. The statistical significance was established using the non-
parametric Mann-Whitney test. * indicates p< 0.05, ** indicates p<0.001
A
T
R
O
G
IN
1
Microarray RNA-Seq qRT-PCR
B
E
C
L
IN
1
B
G
N
C
IL
P
B
N
IP
3
C
O
L
1
A
2
Microarray RNA-Seq qRT-PCR
C
O
L
3
A
1
C
T
G
F
F
N
1
L
U
M
M
G
P
M
Y
H
1
C
D
K
1
N
 (
P
2
1
)
T
G
F
B
1
T
H
B
S
4
T
P
5
3
**
** **
**
** ** **
*
**
** **
* *
*
** ** **
CNTRL
COL6RD
*
*
**
**
**
**
** **
**
** ** **
**
*
4.6 - Validation of selected protein targets
We further performed protein validation of some of the products included in the first 20 most 
upregulated genes  and somehow related to  collagen VI,  and Beclin1,  Lc3b because  previously 
implicated in the pathogenetic mechanisms of the Col6a1-/- mouse model of collagen VI-deficiency 
(Grumati et al., 2010). The western blotting analysis was performed on 4 controls and 9 COL6RD 
muscle biopsies. Thrombospondin-4, decorin and biglycan protein levels were variably upregulated 
in muscle biopsies. Beclin1 and Lc3b protein levels were variable throughout the sample pool, but 
generally not significantly different between controls and COL6RD. 
TGFβ1 was predicted by the upstream regulator analysis performed with Ingenuity Pathway 
Analysis as activated in COL6RD muscle biopsies. To explore further this pathway we performed 
protein validation of the phospshorylated form of Smad2 and total Smad2. Our results showed that 
there were no increase in the level of phosphorylated-Smad2 in COL6RD muscle biopsies when 
compared to normal controls. The protein level of Smad2 were unchanged between normal controls 
and COL6RD muscle biopsies. (Figure 9, upper panel).
We further assessed the localization of THBS4 by immunofluorescence. We probed controls 
(n=3) and COL6RD muscle biopsies (n=4) with antibodies recognizing THBS4 and calnexin, an 
endoplasmic reticulum marker, and perlecan as skeletal muscle basal lamina marker. As the images 
show, THBS4 protein levels are upregulated in the patients muscle biopsies compared to controls. 
Also, while in controls THBS4 seems to be localized mostly around the endomysial capillaries, also 
identified by perlecan, and somewhat around the nuclei almost coinciding with calnexin staining, in 
the COL6RD muscle biopsies THBS4 localizes mostly along the periphery of the skeletal muscle 
fibers. Despite some level of colocalization with calnexin, the majority of THBS4 does not perfectly 
overlay with the ER stain (Figure 9 lower panel).  
 39
  40
C
o
n
tr
o
l
U
C
1
7
9
DCN
BECN1
GAPDH
LC3
BGN
THBS4
PSMAD2
SMAD2
GAPDH
U
C
2
2
0
U
C
3
9
7
.1
U
C
5
6
U
C
5
1
M
1
3
-3
2
M
1
3
-2
1
M
1
3
-7
M
1
3
-6
U
C
2
6
4
U
C
1
7
9
U
C
1
0
0
U
C
9
9
M
1
3
-3
2
M
1
3
-2
1
M
1
3
-7
M
1
3
-6
U
C
3
8
4
C
O
N
T
R
O
L
U
C
17
9
DCN
BECN1
GAPDH
LC3
BGN
THBS4
PSMAD2
SMAD2
GAPDH
UC
22
UC
39
7.1
UC
56
UC
51
M
13
-3
2
M
13
-2
1
M
13
-7
M
13
-6
UC
26
4
UC
17
9
UC
10
0
UC
99
M
13
-3
2
-
1
M
13
-7
M
13
-6
UC
38
4
DAPI PERLECAN THBS4 CALNEXIN MERGE
Figure 9. Protein validation.
Protein validation performed by western blot (upper) and immunofluorescence (lower) on controls (n=3) and COL6RD (n=3) muscle 
biopsies. Magnification 63X. The scale bar corresponds to 50 μm. 
5 - DISCUSSION
The aim of the present study was to investigate pathophysiological pathways involved in the 
determination of the different histological states of the collagen VI-related muscular dystrophies 
(COL6RD). We performed microarray-based and RNA-Seq - based gene expression profiling in the 
same  set  of  COL6RD muscle  biopsies  and  normal  controls  to  characterize  the  progression  of 
COL6RD as reflected by relative gene expression and transcript  patterns and we compared the two 
different approaches to expression profiling. 
We also proposed a systematic review and histological  classification of COL6RD muscle 
biopsies aided by an automated image analysis algorithm, along with two different approaches to 
gene expression profiling, microarray and RNA-Seq. We showed that different histological stages of 
COL6RD are characterized by the same pattern of gene expression with consequent no correlation 
between  the  histopathological  changes  in  COL6RD  muscle  biopsies  and  the  relative  gene 
expression patterns. Rather, even in the early biopsies without histological evidence for fibrosis the 
extracellular  matrix  signature  was already fully  established.  This  observation helps  to  establish 
COL6RD as a primary disorder of the muscle extracellular matrix. Our results also suggested that 
TGFβ1 act as a major driver of the pathological changes at the skeletal muscle level. Moreover, 
muscle  biopsies  from COL6RD patients  are  characterized by an  increase  in  alternative  spliced 
isoforms  of  extracellular  matrix-related  genes  that  might  contribute  to  the  pathogenesis  of  the 
disease.
In skeletal  muscle,  collagen type VI is  produced by the interstitial  fibroblasts  and it  is 
thought to anchor the basement membrane in the skeletal muscle by interacting with collagen IV, a 
major  component  of  the  basal  lamina,  and  other  ECM  component  like  biglycan  and  decorin 
(Bidanset et  al.,  1992; Kuo et al.,  1997; Wiberg et al.,  2001; Zou et al.,  2008).  Unbiased gene 
ontology  analysis  of  the  differentially  regulated  genes  identified  genes  terms  related  to  the 
extracellular matrix, all of them being upregulated in COL6RD muscle biopsies. Among the first 20 
most upregulated genes in COL6RD muscle biopsies we identified fibril-forming collagens, such as 
COL1A2 and COL3A1, and the extracellular matrix proteoglycans biglycan, decorin, and lumican. 
This findings can be ascribed to two different processes. The first is the development of fibrosis, 
which is a prominent characteristics of muscle histology in COL6RD. In this case, the upregulation 
of extracellular matrix components would indicate increased synthesis of non functional connective 
tissue. These findings are common to other neuromuscular disorders, such as Duchenne muscular 
dystrophy, limb girdle muscular dystrophy 2A, Pompe disease (Bakay et al., 2002; Haslett et al., 
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2002; Palermo et al.,  2012; Saenz et al.,  2008; Zanotti et al.,  2005). The second reason for the 
upregulation of extracellular matrix component, particularly of biglycan and decorin, might be a 
tentative to reorganize and preserve the extracellular matrix-skeletal muscle interface due to the 
absence or mislocalization of collagen VI. Previous studies have shown that decorin and biglycan 
have the ability to bind collagen I and collagen VI, and biglycan can also bind α- and γ-sarcoglycan 
of the dystrophin-sarcoglycan complex in skeletal muscle (Rafii et al., 2006; Wiberg et al., 2001). 
When secreted in the extracellular matrix, they cooperate in the process of fibrillogenesis, especially 
in cartilage and tendons. Absence of decorin and biglycan appear to alter strength and stiffness of 
tendons, reinforcing their role in organizing the connective tissue (G. Zhang et al., 2006). Given the 
localization and the role that these small proteoglycans play in the extracellular matrix, it is possible 
that decorin and biglycan are being upregulated in response to the absence of collagen VI to rescue 
the function of the extracellular matrix, to preserve the anchorage of the muscle to the matrix and to 
preserve its biomechanic properties by acting on collagen I and other extracellular matrix proteins 
to reorganize the collagen fibrils, and to the basement membrane of the skeletal muscle to maintain 
the integrity of the system as a whole. 
Interestingly, the upregulation of the extracellular matrix components was also present in the 
less  severe  group  of  COL6RD muscle  biopsies,  where  there  were  no  histological  evidence  of 
fibrosis yet. Inter individual variability due to different genetic backgrounds of the participants to 
this study might play a role in modulating the individual response to pathologic stimuli, together 
with environmental factors. In this specific case, genetic modifiers present in a subgroup of the 
patients population might have contributed to the rate at which the fibrosis progresses, despite the 
early  activation  of  pro-fibrotic  signals,  delaying  the  histological  appearance  of  fibrosis.  At  the 
molecular level, protein synthesis leading to connective tissue deposition might have overcome the 
protein  degradation  of  the  same  extra  connective  tissue.  Metalloproteinases  (MMPs),  Zn2+  -
dependent extracellular endopeptidases, are the major agents in charge of the protein degradation of 
extracellular components and play an important role in skeletal muscle physiology and pathology 
(Sbardella et al., 2015). Some MMPs are closely dependent on specific extracellular matrix partners 
to be fully activated and functional. In the specific case of COL6RD, it can be speculated that at the 
earlier stages of the disease, when the muscle is not severely compromised, the MMPs still function 
within their optimal level range, and they can still compensate for the pathological deposition of 
connective tissue by degrading it, despite the early raise of fibrosis-related genes. As the disease 
progresses,  the  muscle  and  the  matrix  become less  and  less  functional,  the  MMPs might  lose 
contact  with functional  partners  or  get  locked in the matrix so they fail  to  compensate for  the 
 42
deposition of ECM, and the protein synthesis of collagens overcome their degradation, leading to a 
progressive  and  degenerative  fibrotic  process.  All  of  these  hypothesis  would  required  further 
targeted investigation to be proven or otherwise disproven.
The gene expression profiling performed in the present study identified an extensive network 
of  genes that  are known targets  of  the TGFβ/Smad2/3 axis,  corroborated also by the upstream 
regulators  analysis  suggesting  that  TGFβ1  signaling  is  activated  and  upregulated  in  COL6RD 
muscle biopsies. Among the most upregulated genes regulated by TGFβ  there are fibril-forming 
collagens  (i.e.  COL1A1,  COL1A2,  COL3A1),  other  extracellular  matrix  proteins  (i.e.  BGN, 
LTBP2, FN1), and integrins (ITGAV, ITGB2). However, although we assessed the gene and protein 
upregulation of downstream targets of TGFβ1, we did not observed any transcriptional regulation of 
the SMADs and, concordantly, we did not observed an increase in the phosphorylation of Smad2, 
effector of the TGFβ1 canonical pathway. This can be partially explained if we consider that in this 
particular case TGFβ1 might not act through the canonical Smad-dependent pathway, rather via the 
non canonical pathways that involve other key proteins, such as Erk, Jnk, and Rho-GTPase. The 
upstream  regulator  analysis  performed  with  Ingenuity  Pathway  Analysis  would  support  the 
activation of non canonical pathways for  TGFβ1 (Y. E. Zhang, 2009). However, further studies are 
needed to gain insights about this process.
The most upregulated gene in our dataset was Thrombospondin-4 (THBS4). Expression of 
THBS4 is restricted to skeletal and cardiac muscle, and to the nervous system. In skeletal muscle, 
THBS4 is mainly expressed by interstitial cells and it is particularly abundant in the endomysium 
and perimysium of oxidative muscles (i.e. soleus), as well as in tendons, where it regulates the 
structure of the collagen fibrils (Arber & Caroni, 1995; Frolova et al., 2014). Although the function 
of THBS4 in skeletal muscle remains to be elucidated, it was recently reported that THBS4 might 
have a protective role in myocardial remodeling by regulating matrix deposition by fibroblasts and 
fibrosis independent of inflammation (Frolova et al., 2012). In the absence of functional data on 
THBS4 role in skeletal  muscle,  we can speculate  that  the increase in expression of  THBS4 in 
COL6RD may reflect either an attempt to prevent or reduce the deposition of connective tissue 
therefore counteracting the fibrogenic process, or a yet not known contribution to the pathogenesis 
of COL6RD by aberrantly regulating the structure of the collagen fibrils.  Recently, intracellular 
THBS4 has been shown to interact with the protein ATF6, sensor of misfolded protein in the ER and 
effector of the response to ER stress, in cardiomyocites (Lynch et al., 2012). In this study, THBS4 
and other members of the Thrombospondins family would produce a protective ER stress response 
through ATF6 activation. Although we cannot exclude such a role in skeletal muscle, we did not 
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observe the upregulation of typical ER stress markers, and we did not observe a strict colocalization 
of THBS4 and the ER marker calnexin. Therefore, the role of THBS4 in ER stress response in 
skeletal muscle remains to be confirmed. 
One finding from our gene expression profiling which appears to be specific to COL6RD, as 
it has not yet been reported in other muscular dystrophies, is the overexpression of cartilage specific 
genes.  Cartilage  intermediate  layer  protein  (CILP)  is  a  gene  specifically  expressed  in  articular 
cartilage and it is absent from non cartilaginous tissues. This protein is synthesized and deposited in 
the extracellular matrix by chondrocytes. Although the physiological function of the CILP protein 
remains largely unclear, it has been implicated in calcium crystal deposition in articular cartilage in 
patients with osteoarthritis and rheumatoid arthritis in response to age and increased concentration 
of  TGFβ1 (Hirose,  Masuda,  & Ryan,  2000;  Lorenzo,  Bayliss,  & Heinegard,  1998;  Mori  et  al., 
2006). To date, there is no literature reporting expression of CILP by myofibers, muscle interstitial 
cells (i.e. fibroblasts), or muscle derived mesenchymal stem cells. MGP is another gene upregulated 
in the muscle biopsies of COL6RD patients. It codes for a secreted vitamin K-dependent protein 
synthesized by a broad range of tissues and cells, including fibroblasts, chondrocytes, osteoblasts, 
and vascular endothelial cells. Despite the broad tissue distribution of MGP, only cartilage, bone, 
and  calcified  cartilage  have  shown  to  accumulate  significant  levels  of  MGP (Cancela,  Hsieh, 
Francke, & Price, 1990). One reported function of MGP is the inhibition of calcification of soft 
connective  tissues.  MGP-deficient  mice  shows extensive  calcification of  the  aorta  and articular 
cartilage (Gheduzzi et al., 2007; Luo et al., 1997). Our study demonstrated an approximately 3-fold 
increase  in  MGP and an approximately  5-fold  increased in  CILP in  COL6RD muscle  biopsies 
compared to controls.  Interestingly,  MGP and CILP are reported to have opposite effects when 
secreted in the extracellular matrix. 
It  is  well  known  that  muscle  derived  mesenchymal  stem  cells  and  fibroblasts  can 
transdifferentiate in other cell types, like chondrocytes, osteoblasts, adipocyte, and myofibroblasts if 
stimulated  by  specific  growth  factors  (Agley,  Rowlerson,  Velloso,  Lazarus,  &  Harridge,  2013; 
Alexeev et al., 2014). TGFβ1 is the major candidates for driving the transdifferentiation process. It 
was previously reported that mesenchymal stem cells can differentiate in chondrocytes if subjected 
to TGFβ1 stimulation (Johnstone, Hering, Caplan, Goldberg, & Yoo, 1998; Palmer et al., 2005). 
Moreover,  TGFβ1  can  promote  transdifferentiation  of  myoblasts  and  fibroblasts  in  vitro  in 
myofibroblasts through the Smad2/3-dependent upregulation of SK1 and S1P3 (Bruno et al., 2015; 
Cencetti,  Bernacchioni,  Nincheri,  Donati,  & Bruni,  2010;  Wu,  Zhang,  Salmon,  Lin,  & Zehner, 
2007).  The  level  at  which  this  upregulation  occurs  is  still  unknown.  It  might  be  caused  by 
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deregulation of intracellular signals that fail to inhibit Smad2/3/4 action. In alternative, it might be 
caused  by  an  increased  biosynthesis  of  TGFβ1  protein,  or  a  persistence  of  TGFβ1  caused  by 
alterations  in  the  ECM structure  that  entrap  TGFβ1  preventing  its  degradation  and  making  it 
available for longer periods to its receptor. Therefore, a possible explanation for the presence of 
cartilage  and bone specific genes  (i.e.  CILP and MGP) in  the  muscle  biopsies  from COL6RD 
patients is that either fibroblasts from the muscle interstitium, or muscle derived mesenchymal stem 
cells transdifferentiated into other cell types due to an deregulation or mislocalization of key growth 
factors and critical signaling pathways (i.e. TGFβ1 canonical or non canonical pathway). In turn, 
this would cause the activation of signals intended to counteract the differentiation stimuli or the 
effects thereof, in this case carried out by MGP.
The modulation of gene expression is achieved by a diverse multitude of transcriptional and 
post-transcriptional  mechanisms.  Non-coding  RNA-mediated  gene  regulation  has  catalyzed  the 
attention being implicated in controlling physiological and diseased states in skeletal muscle , and 
being a potential therapeutic strategy for many neuromuscular disorders (Eisenberg, Alexander, & 
Kunkel,  2009; Muntoni & Wood, 2011). About a 40% of the differentially regulated transcripts 
identified by RNA-Seq in COL6RD were non protein coding, which leaves room for speculations 
implicating non coding RNA (i.e.  lncdRNA, miRNA) in  the modulation of  gene expression in 
COL6RD. However, further investigation is needed to gain specific and detailed insight into the 
roles and functions of regulatory RNAs in COL6RD.
Microarray and RNA-Seq have been use before to compare transcriptomic datasets deriving 
from the same RNA preparation in many fields, including cancer and immunology (Xu et al., 2013; 
Zhao,  Fung-Leung,  Bittner,  Ngo,  &  Liu,  2014).  The  general  consensus  is  that  there  is  strong 
concordance between microarray and RNA-Seq gene expression measurement across the platforms. 
This was confirmed also in the present study, where we show a correlation in both direction and 
magnitude of the fold change greater than 0.8. However, in our study, microarray detected more 
significantly differentially expressed genes when compared to RNA-Seq, which is generally the 
opposite of what happened in previous studies (Marioni, Mason, Mane, Stephens, & Gilad, 2008; 
Mortazavi, Williams, McCue, Schaeffer, & Wold, 2008). This might be due to the more stringent 
statistical analysis applied. For example, considering the normalized data prior to statistical testing, 
RNA-Seq and microarray detected the same genes. However, many genes detected by RNA-Seq 
failed to pass the false discovery rate threshold. The same phenomenon was observed with regards 
of the microarray for the FN1 gene, which was detected by RNA-Seq and validated by qPCR, but it 
failed to pass the statistical significance test when considering microarray. 
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Interestingly, we observed that roughly 30% of the total reads obtained by RNA-Seq for each 
sample were spread over only 24 genes, out of more than 57,000 known genes present in the human 
genome, with an average fold change magnitude lower than 1.5, therefore below the cutoff and not 
selected for further consideration. These 24 genes were represented mostly by different types of 
myosin, thus strictly skeletal muscle-specific genes, and GAPDH, abundantly present in any type of 
tissue. This introduces a major bias when performing RNA-Seq versus microarray. In fact, while 
microarray provide limited dynamic range, the coverage is evenly distributed among all the genes 
represented on the array. On the other hand, RNA-Seq provides virtually unlimited dynamic range, 
but  coverage  can  result  uneven  in  favor  of  overrepresented  genes  that  are  not  necessarily 
differentially expressed among samples, but that would take over the available sequencing depth, 
therefore providing a major bias against poorly expressed genes. This is the reason why, in our 
study, RNA-Seq detected less genes than microarray in general (8234 of microarray vs 2889 of 
RNA-Seq), and of these fewer were statistically significant between COL6RD and controls. 
Despite some bias dictated by the method, the technical validation analysis with qRT-PCR 
done on genes detected by both platforms suggested that both microarray and RNA-Seq were highly 
reliable and reproducible to detect gene expression differences.
With  the  present  study,  we  intend  to  offer  a  transcriptomic  approach  to  the  study  of 
COL6RD, in an effort to understand the molecular pathways responsible for the pathogenesis and 
the progression of the disease. Our results also suggest that TGFβ1 dependent pathways act as a 
major driver of the pathological changes at the skeletal muscle level in COL6RD, offering a new 
therapeutic approach to treat this specific subtype of neuromuscular disorder.  
 46
6 - BIBLIOGRAPHY
Agley, C. C., Rowlerson, A. M., Velloso, C. P., Lazarus, N. R., & Harridge, S. D. (2013). 
Human  skeletal  muscle  fibroblasts,  but  not  myogenic  cells,  readily  undergo  adipogenic 
differentiation. J Cell Sci, 126(Pt 24), 5610-5625. doi: 10.1242/jcs.132563
Alexeev,  V.,  Arita,  M.,  Donahue,  A.,  Bonaldo,  P.,  Chu,  M.  L.,  & Igoucheva,  O.  (2014). 
Human adipose-derived  stem cell  transplantation  as  a  potential  therapy for  collagen  VI-related 
congenital muscular dystrophy. Stem Cell Res Ther, 5(1), 21. doi: 10.1186/scrt411
Arber, S., & Caroni, P. (1995). Thrombospondin-4, an extracellular matrix protein expressed 
in  the  developing  and  adult  nervous  system  promotes  neurite  outgrowth.  J  Cell  Biol,  131(4), 
1083-1094. 
Arts, W. F., Bethlem, J., & Volkers, W. S. (1978). Further investigations on benign myopathy 
with autosomal dominant inheritance. J Neurol, 217(3), 201-206. 
Bakay,  M.,  Zhao,  P.,  Chen,  J.,  &  Hoffman,  E.  P.  (2002).  A web-accessible  complete 
transcriptome of normal human and DMD muscle. Neuromuscul Disord, 12 Suppl 1, S125-141. 
Baker,  N. L.,  Morgelin,  M.,  Pace, R. A.,  Peat,  R. A.,  Adams, N. E.,  Gardner,  R. J.,  .  .  . 
Lamande,  S.  R.  (2007).  Molecular  consequences  of  dominant  Bethlem  myopathy  collagen  VI 
mutations. Ann Neurol, 62(4), 390-405. doi: 10.1002/ana.21213
Baker, N. L., Morgelin, M., Peat, R., Goemans, N., North, K. N., Bateman, J. F., & Lamande, 
S. R. (2005). Dominant collagen VI mutations are a common cause of Ullrich congenital muscular 
dystrophy. Hum Mol Genet, 14(2), 279-293. doi: 10.1093/hmg/ddi025
Bethlem,  J.,  &  Wijngaarden,  G.  K.  (1976).  Benign  myopathy,  with  autosomal  dominant 
inheritance. A report on three pedigrees. Brain, 99(1), 91-100. 
Bidanset, D. J., Guidry, C., Rosenberg, L. C., Choi, H. U., Timpl, R., & Hook, M. (1992). 
Binding of the proteoglycan decorin to collagen type VI. J Biol Chem, 267(8), 5250-5256. 
Bruno,  G.,  Cencetti,  F.,  Pertici,  I.,  Japtok,  L.,  Bernacchioni,  C.,  Donati,  C.,  & Bruni,  P. 
(2015). CTGF/CCN2 exerts profibrotic action in myoblasts via the up-regulation of sphingosine 
kinase-1/S1P3 signaling axis: Implications in the action mechanism of TGFbeta. Biochim Biophys 
Acta, 1851(2), 194-202. doi: 10.1016/j.bbalip.2014.11.011
Bruns, R. R. (1984). Beaded filaments and long-spacing fibrils: relation to type VI collagen. J 
Ultrastruct Res, 89(2), 136-145. 
Butterfield, R. J., Foley, A. R., Dastgir, J., Asman, S., Dunn, D. M., Zou, Y., . . . Bonnemann, 
C.  G.  (2013).  Position  of  glycine  substitutions  in  the  triple  helix  of  COL6A1,  COL6A2,  and 
 47
COL6A3 is  correlated with  severity  and mode of  inheritance in  collagen VI myopathies.  Hum 
Mutat, 34(11), 1558-1567. doi: 10.1002/humu.22429
Cancela,  L.,  Hsieh,  C.  L.,  Francke,  U.,  &  Price,  P.  A.  (1990).  Molecular  structure, 
chromosome assignment, and promoter organization of the human matrix Gla protein gene. J Biol 
Chem, 265(25), 15040-15048. 
Cencetti,  F.,  Bernacchioni,  C.,  Nincheri,  P.,  Donati,  C.,  & Bruni,  P. (2010).  Transforming 
growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation 
of sphingosine kinase-1/S1P3 axis. Mol Biol Cell, 21(6), 1111-1124. doi: 10.1091/mbc.E09-09-0812
Chu, M. L., Mann, K., Deutzmann, R., Pribula-Conway, D., Hsu-Chen, C. C., Bernard, M. P., 
& Timpl, R. (1987). Characterization of three constituent chains of collagen type VI by peptide 
sequences and cDNA clones. Eur J Biochem, 168(2), 309-317. 
Chu, M. L., Pan, T. C., Conway, D., Kuo, H. J., Glanville, R. W., Timpl, R., . . . Deutzmann, 
R. (1989). Sequence analysis of alpha 1(VI) and alpha 2(VI) chains of human type VI collagen 
reveals internal triplication of globular domains similar to the A domains of von Willebrand factor 
and two alpha 2(VI) chain variants that differ in the carboxy terminus. EMBO J, 8(7), 1939-1946. 
Demir, E., Sabatelli, P., Allamand, V., Ferreiro, A., Moghadaszadeh, B., Makrelouf, M., . . . 
Guicheney,  P.  (2002).  Mutations  in  COL6A3  cause  severe  and  mild  phenotypes  of  Ullrich 
congenital muscular dystrophy. Am J Hum Genet, 70(6), 1446-1458. doi: 10.1086/340608
Eisenberg, I., Alexander, M. S., & Kunkel, L. M. (2009). miRNAS in normal and diseased 
skeletal muscle. J Cell Mol Med, 13(1), 2-11. doi: 10.1111/j.1582-4934.2008.00524.x
Engel, J., Furthmayr, H., Odermatt, E., von der Mark, H., Aumailley, M., Fleischmajer, R., & 
Timpl, R. (1985). Structure and macromolecular organization of type VI collagen. Ann N Y Acad 
Sci, 460, 25-37. 
Fitzgerald, J., Rich, C., Zhou, F. H., & Hansen, U. (2008). Three novel collagen VI chains, 
alpha4(VI),  alpha5(VI),  and  alpha6(VI).  J  Biol  Chem,  283(29),  20170-20180.  doi:  10.1074/
jbc.M710139200
Foley, A. R., Hu, Y., Zou, Y., Columbus, A., Shoffner, J., Dunn, D. M., . . . Bonnemann, C. G. 
(2009). Autosomal recessive inheritance of classic Bethlem myopathy. Neuromuscul Disord, 19(12), 
813-817. doi: 10.1016/j.nmd.2009.09.010
Frolova, E. G., Drazba, J., Krukovets, I., Kostenko, V., Blech, L., Harry, C., . . . Stenina-
Adognravi,  O.  (2014).  Control  of  organization  and  function  of  muscle  and  tendon  by 
thrombospondin-4. Matrix Biol, 37, 35-48. doi: 10.1016/j.matbio.2014.02.003
 48
Frolova, E. G., Sopko, N., Blech, L., Popovic, Z. B., Li, J., Vasanji, A., . . . Stenina, O. I. 
(2012).  Thrombospondin-4 regulates fibrosis  and remodeling of  the myocardium in response to 
pressure overload. FASEB J, 26(6), 2363-2373. doi: 10.1096/fj.11-190728
Furukawa, T., & Toyokura, Y. (1977). Congenital, hypotonic-sclerotic muscular dystrophy. J 
Med Genet, 14(6), 426-429. 
Gara, S. K., Grumati, P., Urciuolo, A., Bonaldo, P., Kobbe, B., Koch, M., . . . Wagener, R. 
(2008). Three novel collagen VI chains with high homology to the alpha3 chain. J Biol Chem, 
283(16), 10658-10670. doi: 10.1074/jbc.M709540200
Garber, M., Grabherr, M. G., Guttman, M., & Trapnell, C. (2011). Computational methods 
for transcriptome annotation and quantification using RNA-seq. Nat Methods, 8(6), 469-477. doi: 
10.1038/nmeth.1613
Gheduzzi, D., Boraldi, F., Annovi, G., DeVincenzi, C. P., Schurgers, L. J., Vermeer, C., . . . 
Ronchetti, I. P. (2007). Matrix Gla protein is involved in elastic fiber calcification in the dermis of 
pseudoxanthoma elasticum patients. Lab Invest, 87(10), 998-1008. doi: 10.1038/labinvest.3700667
Giusti, B., Lucarini, L., Pietroni, V., Lucioli, S., Bandinelli, B., Sabatelli, P., . . . Pepe, G. 
(2005). Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. 
Ann Neurol, 58(3), 400-410. doi: 10.1002/ana.20586
Grumati, P., Coletto, L., Sabatelli, P., Cescon, M., Angelin, A., Bertaggia, E., . . . Bonaldo, P. 
(2010). Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues 
myofiber degeneration. Nat Med, 16(11), 1313-1320. doi: 10.1038/nm.2247
Gualandi,  F.,  Urciuolo,  A.,  Martoni,  E.,  Sabatelli,  P.,  Squarzoni,  S.,  Bovolenta,  M.,  .  .  . 
Merlini,  L. (2009). Autosomal recessive Bethlem myopathy. Neurology, 73(22), 1883-1891. doi: 
10.1212/WNL.0b013e3181c3fd2a
Haslett, J. N., Sanoudou, D., Kho, A. T., Bennett, R. R., Greenberg, S. A., Kohane, I. S., . . . 
Kunkel, L. M. (2002). Gene expression comparison of biopsies from Duchenne muscular dystrophy 
(DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A, 99(23), 15000-15005. doi: 10.1073/
pnas.192571199
Hirose,  J.,  Masuda,  I.,  & Ryan,  L.  M. (2000).  Expression of  cartilage intermediate  layer 
protein/nucleotide  pyrophosphohydrolase  parallels  the  production  of  extracellular  inorganic 
pyrophosphate in response to growth factors and with aging. Arthritis Rheum, 43(12), 2703-2711. 
doi: 10.1002/1529-0131(200012)43:12<2703::AID-ANR10>3.0.CO;2-Y
 49
Irwin,  W.  A.,  Bergamin,  N.,  Sabatelli,  P.,  Reggiani,  C.,  Megighian,  A.,  Merlini,  L.,  .  .  . 
Bonaldo, P. (2003). Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI 
deficiency. Nat Genet, 35(4), 367-371. doi: 10.1038/ng1270
Jobsis, G. J., Keizers, H., Vreijling, J. P., de Visser, M., Speer, M. C., Wolterman, R. A., . . . 
Bolhuis, P. A. (1996). Type VI collagen mutations in Bethlem myopathy, an autosomal dominant 
myopathy with contractures. Nat Genet, 14(1), 113-115. doi: 10.1038/ng0996-113
Johnstone, B., Hering, T. M., Caplan, A. I., Goldberg, V. M., & Yoo, J. U. (1998). In vitro 
chondrogenesis  of  bone  marrow-derived  mesenchymal  progenitor  cells.  Exp  Cell  Res,  238(1), 
265-272. doi: 10.1006/excr.1997.3858
Kuo, H. J., Keene, D. R., & Glanville, R. W. (1995). The macromolecular structure of type-
VI collagen. Formation and stability of filaments. Eur J Biochem, 232(2), 364-372. 
Kuo, H. J., Maslen, C. L., Keene, D. R., & Glanville, R. W. (1997). Type VI collagen anchors 
endothelial  basement  membranes  by  interacting  with  type  IV collagen.  J  Biol  Chem,  272(42), 
26522-26529. 
Lamande, S. R., Bateman, J. F., Hutchison, W., McKinlay Gardner, R. J., Bower, S. P., Byrne, 
E., & Dahl, H. H. (1998). Reduced collagen VI causes Bethlem myopathy: a heterozygous COL6A1 
nonsense mutation results in mRNA decay and functional haploinsufficiency. Hum Mol Genet, 7(6), 
981-989. 
Lamande, S. R., Morgelin, M., Selan, C., Jobsis, G. J., Baas, F., & Bateman, J. F. (2002). 
Kinked collagen VI tetramers and reduced microfibril formation as a result of Bethlem myopathy 
and introduced triple helical  glycine mutations.  J Biol  Chem, 277(3),  1949-1956.  doi:  10.1074/
jbc.M109932200
Lamande, S. R.,  Shields, K. A., Kornberg, A. J.,  Shield, L. K., & Bateman, J.  F. (1999). 
Bethlem  myopathy  and  engineered  collagen  VI  triple  helical  deletions  prevent  intracellular 
multimer assembly and protein secretion. J Biol Chem, 274(31), 21817-21822. 
Lamande, S. R., Sigalas, E., Pan, T. C., Chu, M. L., Dziadek, M., Timpl, R., & Bateman, J. F. 
(1998). The role of the alpha3(VI) chain in collagen VI assembly. Expression of an alpha3(VI) 
chain lacking N-terminal modules N10-N7 restores collagen VI assembly, secretion, and matrix 
deposition in an alpha3(VI)-deficient cell line. J Biol Chem, 273(13), 7423-7430. 
Lampe, A. K., Zou, Y., Sudano, D., O'Brien, K. K., Hicks, D., Laval, S. H., . . . Bonnemann, 
C. G. (2008). Exon skipping mutations in collagen VI are common and are predictive for severity 
and inheritance. Hum Mutat, 29(6), 809-822. doi: 10.1002/humu.20704
 50
Leyten, Q. H., Gabreels, F. J., Joosten, E. M., Renier, W. O., Ter Laak, H. J., Ter Haar, B. G., 
& Stadhouders, A. M. (1986). An autosomal dominant type of congenital muscular dystrophy. Brain 
Dev, 8(5), 533-537. 
Lorenzo, P., Bayliss, M. T., & Heinegard, D. (1998). A novel cartilage protein (CILP) present 
in  the  mid-zone  of  human  articular  cartilage  increases  with  age.  J  Biol  Chem,  273(36), 
23463-23468. 
Lucarini, L., Giusti, B., Zhang, R. Z., Pan, T. C., Jimenez-Mallebrera, C., Mercuri, E., . . . 
Chu, M. L. (2005). A homozygous COL6A2 intron mutation causes in-frame triple-helical deletion 
and nonsense-mediated mRNA decay in a patient with Ullrich congenital muscular dystrophy. Hum 
Genet, 117(5), 460-466. doi: 10.1007/s00439-005-1318-8
Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R., & Karsenty, G. 
(1997).  Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. 
Nature, 386(6620), 78-81. doi: 10.1038/386078a0
Lynch, J. M., Maillet, M., Vanhoutte, D., Schloemer, A., Sargent, M. A., Blair, N. S., . . . 
Molkentin, J. D. (2012). A thrombospondin-dependent pathway for a protective ER stress response. 
Cell, 149(6), 1257-1268. doi: 10.1016/j.cell.2012.03.050
Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M., & Gilad, Y. (2008). RNA-seq: an 
assessment of technical reproducibility and comparison with gene expression arrays. Genome Res, 
18(9), 1509-1517. doi: 10.1101/gr.079558.108
Mercuri, E., Cini, C., Counsell, S., Allsop, J., Zolkipli, Z., Jungbluth, H., . . . Muntoni, F. 
(2002). Muscle MRI findings in a three-generation family affected by Bethlem myopathy. Eur J 
Paediatr Neurol, 6(6), 309-314. 
Mercuri, E., Cini, C., Pichiecchio, A., Allsop, J., Counsell, S., Zolkipli, Z., . . . Muntoni, F. 
(2003). Muscle magnetic resonance imaging in patients with congenital muscular dystrophy and 
Ullrich phenotype. Neuromuscul Disord, 13(7-8), 554-558. 
Mercuri, E., Lampe, A., Allsop, J., Knight, R., Pane, M., Kinali, M., . . . Muntoni, F. (2005). 
Muscle  MRI  in  Ullrich  congenital  muscular  dystrophy  and  Bethlem  myopathy.  Neuromuscul 
Disord, 15(4), 303-310. doi: 10.1016/j.nmd.2005.01.004
Merlini, L., Angelin, A., Tiepolo, T., Braghetta, P., Sabatelli, P., Zamparelli, A., . . . Bernardi, 
P. (2008). Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with 
collagen  VI  myopathies.  Proc  Natl  Acad  Sci  U  S  A,  105(13),  5225-5229.  doi:  10.1073/pnas.
0800962105
 51
Merlini, L., Morandi, L., Granata, C., & Ballestrazzi, A. (1994). Bethlem myopathy: early-
onset benign autosomal dominant myopathy with contractures. Description of two new families. 
Neuromuscul Disord, 4(5-6), 503-511. 
Mohire, M. D., Tandan, R., Fries, T. J., Little, B. W., Pendlebury, W. W., & Bradley, W. G. 
(1988). Early-onset benign autosomal dominant limb-girdle myopathy with contractures (Bethlem 
myopathy). Neurology, 38(4), 573-580. 
Mori, M., Nakajima, M., Mikami, Y., Seki, S., Takigawa, M., Kubo, T., & Ikegawa, S. (2006). 
Transcriptional regulation of the cartilage intermediate layer protein (CILP) gene. Biochem Biophys 
Res Commun, 341(1), 121-127. doi: 10.1016/j.bbrc.2005.12.159
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008). Mapping and 
quantifying mammalian transcriptomes by RNA-Seq. Nat Methods, 5(7), 621-628. doi: 10.1038/
nmeth.1226
Muntoni, F., & Wood, M. J. (2011). Targeting RNA to treat neuromuscular disease. Nat Rev 
Drug Discov, 10(8), 621-637. doi: 10.1038/nrd3459
Ozsolak, F., & Milos, P. M. (2011). RNA sequencing: advances, challenges and opportunities. 
Nat Rev Genet, 12(2), 87-98. doi: 10.1038/nrg2934
Paco, S., Kalko, S. G., Jou, C., Rodriguez, M. A., Corbera, J., Muntoni, F., . . . Jimenez-
Mallebrera,  C.  (2013).  Gene expression profiling identifies  molecular  pathways associated with 
collagen  VI  deficiency  and  provides  novel  therapeutic  targets.  PLoS  One,  8(10),  e77430.  doi: 
10.1371/journal.pone.0077430
Palermo, A. T., Palmer, R. E., So, K. S., Oba-Shinjo, S. M., Zhang, M., Richards, B., . . . 
Pomponio, R. J. (2012). Transcriptional response to GAA deficiency (Pompe disease) in infantile-
onset patients. Mol Genet Metab, 106(3), 287-300. doi: 10.1016/j.ymgme.2012.05.004
Palmer, G. D., Steinert, A., Pascher, A., Gouze, E., Gouze, J. N., Betz, O., . . . Ghivizzani, S. 
C. (2005). Gene-induced chondrogenesis of primary mesenchymal stem cells in vitro. Mol Ther, 
12(2), 219-228. doi: 10.1016/j.ymthe.2005.03.024
Palstra, A. P., Beltran, S., Burgerhout, E., Brittijn, S. A., Magnoni, L. J., Henkel, C. V., . . . 
Planas, J. V. (2013). Deep RNA sequencing of the skeletal muscle transcriptome in swimming fish. 
PLoS One, 8(1), e53171. doi: 10.1371/journal.pone.0053171
Pan, T. C., Zhang, R. Z., Pericak-Vance, M. A., Tandan, R., Fries, T., Stajich, J. M., . . . Speer, 
M. C. (1998). Missense mutation in a von Willebrand factor type A domain of the alpha 3(VI) 
collagen gene (COL6A3) in a family with Bethlem myopathy. Hum Mol Genet, 7(5), 807-812. 
 52
Pan, T. C., Zhang, R. Z., Sudano, D. G., Marie, S. K., Bonnemann, C. G., & Chu, M. L. 
(2003). New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-
frame deletion in the COL6A1 gene causes a severe phenotype. Am J Hum Genet, 73(2), 355-369. 
doi: 10.1086/377107
Pepe, G., Bertini, E., Giusti, B., Brunelli, T., Comeglio, P., Saitta, B., . . . Abbate, R. (1999). A 
novel de novo mutation in the triple helix of the COL6A3 gene in a two-generation Italian family 
affected  by  Bethlem myopathy.  A diagnostic  approach  in  the  mutations'  screening  of  type  VI 
collagen. Neuromuscul Disord, 9(4), 264-271. 
Pepe, G., Giusti, B., Bertini, E., Brunelli, T., Saitta, B., Comeglio, P., . . . Chu, M. L. (1999). 
A heterozygous splice site mutation in COL6A1 leading to an in-frame deletion of the alpha1(VI) 
collagen chain in an italian family affected by bethlem myopathy. Biochem Biophys Res Commun, 
258(3), 802-807. doi: 10.1006/bbrc.1999.0680
Pepe, G., Lucarini, L., Zhang, R. Z., Pan, T. C., Giusti, B., Quijano-Roy, S., . . . Chu, M. L. 
(2006). COL6A1 genomic deletions in Bethlem myopathy and Ullrich muscular dystrophy. Ann 
Neurol, 59(1), 190-195. doi: 10.1002/ana.20705
Porter, J. D., Khanna, S., Kaminski, H. J., Rao, J. S., Merriam, A. P., Richmonds, C. R., . . . 
Andrade, F. H. (2002). A chronic inflammatory response dominates the skeletal muscle molecular 
signature in dystrophin-deficient mdx mice. Hum Mol Genet, 11(3), 263-272. 
Rafii, M. S., Hagiwara, H., Mercado, M. L., Seo, N. S., Xu, T., Dugan, T., . . . Fallon, J. R. 
(2006).  Biglycan binds to  alpha-  and gamma-sarcoglycan and regulates  their  expression during 
development. J Cell Physiol, 209(2), 439-447. doi: 10.1002/jcp.20740
Ricci, E., Bertini, E., Boldrini, R., Sabatelli, M., Servidei, S., Mazziotta, M. R., . . . Tonali, P. 
(1988). Late onset scleroatonic familial myopathy (Ullrich disease): a study of two sibs. Am J Med 
Genet, 31(4), 933-942. doi: 10.1002/ajmg.1320310428
Saenz, A., Azpitarte, M., Armananzas, R., Leturcq, F., Alzualde, A., Inza, I., . . . Lopez de 
Munain, A. (2008). Gene expression profiling in limb-girdle muscular dystrophy 2A. PLoS One, 
3(11), e3750. doi: 10.1371/journal.pone.0003750
Saitta, B., Timpl, R., & Chu, M. L. (1992). Human alpha 2(VI) collagen gene. Heterogeneity 
at the 5'-untranslated region generated by an alternate exon. J Biol Chem, 267(9), 6188-6196. 
Saitta,  B.,  Wang, Y. M., Renkart,  L.,  Zhang, R. Z.,  Pan, T. C.,  Timpl, R.,  & Chu, M. L. 
(1991). The exon organization of the triple-helical coding regions of the human alpha 1(VI) and 
alpha 2(VI) collagen genes is highly similar. Genomics, 11(1), 145-153. 
 53
Sasaki, T., Hohenester, E., Zhang, R. Z., Gotta, S., Speer, M. C., Tandan, R., . . . Chu, M. L. 
(2000). A Bethlem myopathy Gly to Glu mutation in the von Willebrand factor A domain N2 of the 
collagen alpha3(VI) chain interferes with protein folding. FASEB J, 14(5), 761-768. 
Sbardella,  D.,  Sciandra,  F.,  Gioia,  M.,  Marini,  S.,  Gori,  A.,  Giardina,  B.,  .  .  .  Bozzi,  M. 
(2015). alpha-dystroglycan is a potential target of matrix metalloproteinase MMP-2. Matrix Biol, 
41, 2-7. doi: 10.1016/j.matbio.2014.11.007
Scacheri,  P.  C.,  Gillanders,  E.  M.,  Subramony,  S.  H.,  Vedanarayanan,  V.,  Crowe,  C.  A., 
Thakore, N., . . . Hoffman, E. P. (2002). Novel mutations in collagen VI genes: expansion of the 
Bethlem myopathy phenotype. Neurology, 58(4), 593-602. 
Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., . . . Ragg, T. 
(2006). The RIN: an RNA integrity number for assigning integrity values to RNA measurements. 
BMC Mol Biol, 7, 3. doi: 10.1186/1471-2199-7-3
Stokes, D. G., Saitta, B., Timpl, R., & Chu, M. L. (1991). Human alpha 3(VI) collagen gene. 
Characterization of exons coding for the amino-terminal globular domain and alternative splicing in 
normal and tumor cells. J Biol Chem, 266(13), 8626-8633. 
Trikka, D., Davis, T., Lapenta, V., Brahe, C., & Kessling, A. M. (1997). Human COL6A1: 
genomic  characterization of  the  globular  domains,  structural  and evolutionary  comparison with 
COL6A2. Mamm Genome, 8(5), 342-345. 
Vanegas, O. C., Zhang, R. Z., Sabatelli, P., Lattanzi, G., Bencivenga, P., Giusti, B., . . . Pepe, 
G.  (2002).  Novel  COL6A1 splicing mutation in  a  family  affected by mild  Bethlem myopathy. 
Muscle Nerve, 25(4), 513-519. 
Wiberg,  C.,  Hedbom,  E.,  Khairullina,  A.,  Lamande,  S.  R.,  Oldberg,  A.,  Timpl,  R.,  .  .  . 
Heinegard, D. (2001). Biglycan and decorin bind close to the n-terminal region of the collagen VI 
triple helix. J Biol Chem, 276(22), 18947-18952. doi: 10.1074/jbc.M100625200
Wu, Y., Zhang, X., Salmon, M., Lin, X., & Zehner, Z. E. (2007). TGFbeta1 regulation of 
vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires 
Smads, AP-1 and Sp1 family members. Biochim Biophys Acta, 1773(3), 427-439. doi: 10.1016/
j.bbamcr.2006.11.017
Xu, X., Zhang, Y., Williams, J., Antoniou, E., McCombie, W. R., Wu, S., . . . Li, E. (2013). 
Parallel comparison of Illumina RNA-Seq and Affymetrix microarray platforms on transcriptomic 
profiles  generated  from  5-aza-deoxy-cytidine  treated  HT-29  colon  cancer  cells  and  simulated 
datasets. BMC Bioinformatics, 14 Suppl 9, S1. doi: 10.1186/1471-2105-14-S9-S1
 54
Zanotti, S., Negri, T., Cappelletti, C., Bernasconi, P., Canioni, E., Di Blasi, C., . . . Mora, M. 
(2005). Decorin and biglycan expression is differentially altered in several muscular dystrophies. 
Brain, 128(Pt 11), 2546-2555. doi: 10.1093/brain/awh635
Zhang, G., Ezura, Y., Chervoneva, I., Robinson, P. S., Beason, D. P., Carine, E. T., . . . Birk, 
D.  E.  (2006).  Decorin  regulates  assembly  of  collagen  fibrils  and  acquisition  of  biomechanical 
properties during tendon development. J Cell Biochem, 98(6), 1436-1449. doi: 10.1002/jcb.20776
Zhang, R. Z., Sabatelli, P., Pan, T. C., Squarzoni, S., Mattioli, E., Bertini, E., . . . Chu, M. L. 
(2002).  Effects  on  collagen  VI  mRNA stability  and  microfibrillar  assembly  of  three  COL6A2 
mutations  in  two  families  with  Ullrich  congenital  muscular  dystrophy.  J  Biol  Chem,  277(46), 
43557-43564. doi: 10.1074/jbc.M207696200
Zhang, Y. E. (2009). Non-Smad pathways in TGF-beta signaling. Cell Res, 19(1), 128-139. 
doi: 10.1038/cr.2008.328
Zhao, S., Fung-Leung, W. P., Bittner, A., Ngo, K., & Liu, X. (2014). Comparison of RNA-
Seq and microarray in transcriptome profiling of activated T cells. PLoS One, 9(1), e78644. doi: 
10.1371/journal.pone.0078644
Zhou,  X.,  Dimachkie,  M.  M.,  Xiong,  M.,  Tan,  F.  K.,  &  Arnett,  F.  C.  (2004).  cDNA 
microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med Sci 
Monit, 10(7), BR191-197. 
Zou,  Y.,  Zhang,  R.  Z.,  Sabatelli,  P.,  Chu,  M.  L.,  &  Bonnemann,  C.  G.  (2008).  Muscle 
interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications 
for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol, 67(2), 
144-154. doi: 10.1097/nen.0b013e3181634ef7
 55
